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Abstract 
Due to its role in regulation of mitochondrial function, PGC1α is emerging 
as an important player in ageing and neurodegenerative disorders. PGC1α 
exerts its neuroprotective effects by promoting mitochondrial biogenesis (MB) 
and functioning. However, the precise regulatory role of PGC1α in the control 
of mitochondrial dynamics (MD) and neurotoxicity is still unknown. Here we 
elucidate the role of PGC1αin vitro and in vivo in the regulatory context of MB 
and MD in response to lead (II) acetate as a relevant model of neurotoxicity. 
We show that there is an adaptive response (AR) to lead, orchestrated by the 
BAP31-calcium signalling system operating between the ER and mitochondria. 
We find that this hormetic response is controlled by a cell-tolerated increase of 
PGC1α expression, which in turn induces a balanced expression of 
fusion/fission genes by binding to their promoters and implying its direct role in 
regulation of MD. However, dysregulation of PGC1α expression through either 
stable downregulation or overexpression, renders cells more susceptible to 
lead insult leading to mitochondrial fragmentation and cell death. Our data 
provide novel evidence that PGC1α expression is a key regulator of MD and 
the maintenance of tolerated PGC1α expression may offer a promising strategy 
for neuroprotective therapies. 
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Introduction 
1.1 Lead and human health 
1.1.1 Lead  
Lead is a chemical element with symbol Pb (an abbreviation of its Latin 
name plumbum meaning ‘liquid silver). It is the heaviest element of the carbon 
family (group IVA) of the periodic table (Fig. 1.1) with an atomic number 82. 
Figure 1.1. Periodic table of elements.  
Taken from http://sciencenotes.org/printable-periodic-table-chart/ 
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This soft, greyish metal has a low melting point and high density. 
Because of the latter property as well as a high number of electrons, lead is 
very efficient at absorbing gamma radiation as well as X-radiation. Pb has four 
naturally occurring stable isotopes:  204Pb, 206Pb, 207Pb and 208Pb, the first three 
of which are used to determine the age of rocks. Native lead is not very 
abundant in the environment and is very rarely found in a free state in nature. 
For commercial purposes, lead is extracted from its ores, most common of 
which are galena (PbS), anglesite (PbSO4), cerussite (PbCO3) and minium 
(Pb3O4).  
1.1.2 Sources of lead 
Environmental accumulation of lead is mainly a result of commercial 
practices. Due to ease of its extraction, malleability and low melting 
temperature, lead has been in use for thousands of years. The oldest lead piece 
ever found dates back to 3800 B.C. and is kept at the British Museum. 
Archeological research shows that this heavy metal started to be commonly 
used in the times of the Roman Empire when it was widely applied in production 
of water pipes (Hodge 1981) by ‘plumbarii’, people working with plumbum 
(hence the current name for plumbers). Moreover, Romans are believed to 
have been exposed to high concentrations of lead by ingestion of this heavy 
metal due to lead pots being commonly used and recommended for wine 
production. Boiling of fruit juice at high temperatures for long hours caused lead 
from the pots to seep and react with acetate ions from acetic acid present in 
fruit juice, resulting in lead acetate formation. This phenomenon gave wine a 
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slightly sweeter taste, a sought-for quality. A recent experiment aimed at re-
creating the above mentioned process using a lead container resulted in 
generation of a liquid with an astounding lead content of 2900 parts per billion. 
After the fall of the Roman Empire commercial lead use has significantly 
dropped. Two other peaks of lead usage occurred during Medieval German 
silver production and the Industrial Revolution.  
 A very important event in modern lead usage was its incorporation 
in petrol. The ‘anti-knock’ properties of leaded fuel were investigated for the first 
time by Thomas Midgley in 1921, who was later on described as a person who 
‘had more impact on the atmosphere than any other single organism in Earth's 
history’  (McNeill 2000). Since first commercial sales of leaded petrol in the 
1920’s, around 50 years passed before the US Environmental Protection 
Agency (EPA) announced in the early 70’s that leaded fuel should be phased 
out due to its toxicity. Since then, it has been almost completely eradicated and 
the main route of exposure to organic lead is occupational. It is the organic lead 
that is the more toxic form of this metal due to the ease of its assimilation by 
the body, including absorption via skin and a very direct and acute effect on the 
nervous system causing an acute toxic psychosis. 
 The inorganic form of lead is less readily absorbed by the body, 
compared with organolead. The main routes of exposure to inorganic lead are 
by ingestion and inhalation. While lead exposure has declined in recent years 
due to a decrease of its usage in fuels, it still poses a threat to human health 
due to its past use in paints and plumbing materials.  While currently inorganic 
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lead contamination can still be found in foods and, to a lesser extent, in drinking 
water, an inorganic form of the metal is also present in different consumer 
products. Nevertheless, while old, lead-containing paint remains the main 
source of environmental inorganic lead in some countries, in most of the 
developed countries food is very often the main source of exposure with cereal 
products being the main contributors (EFSA Panel on Contaminants in the Food 
Chain 2010).  While use of leaded paint has been prohibited by the League of 
Nations since 1922, its ban has been introduced as late as 1978 in the US. 
However, while people stopped using lead-based interior paints, it did not 
change the fact that it stayed on the walls of a vast number houses and 
remained a threat to human health, children in particular due to their hand-to-
mouth behaviour and pica (Jacobs 1995, Clark, Kumar et al. 2014, Gulson 
2014). Shockingly, there are still many countries where lead-based paint can 
be bought (Fig. 1.2).  
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Figure 1.2. Countries in which lead-based paints are still being sold.  
Image taken from EHP (Kessler 2014). 
 
 
 
1 Argentina
2 Armenia
3 Azerbaijan
4 Bangladesh
5 Belarus
6 Brazil
7 Cameroon
8 Chile
9 China
10 Côte d’Ivoire
11 Ecuador
12 Egypt
13 Ethiopia
14 Ghana
15 India
16 Indonesia
17 Kazakhstan
18 Kenya
19 Kyrgyzstan
20 Lebanon
21 Malaysia
22 Mexico
23 Nepal
24 Nigeria
25 Paraguay
26 Peru
27 Philippines
28 Russia
29 Senegal
30 Seychelles
31 Singapore
32 South Africa
33 Sri Lanka
34 Taiwan
35 Tanzania
36 Thailand
37 Tunisia
38 Uganda
39 United Arab Emirates
40 Vietnam
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Use of leaded paint significantly contributed to the elevation of 
environmental lead levels due to the fact that chipping paint results in formation 
of lead-containing dust that can spread easily and causes subsequent 
contamination of soil. Lead resists degradation allowing for sustained 
persistence in the environment. Plants take up lead from soil, air and water and 
can become a direct source of lead exposure when ingested or an indirect one 
by being a source of food for animals that have an intermediate position in the 
food chain (Peralta-Videa, Lopez et al. 2009, Capdevila, Nadal et al. 2003).  
 Surprisingly, there are still many products available which contain 
lead. They are usually low-cost items which in consequence, together with a 
higher likelihood of being exposed to old, lead-containing paint, make the risk 
of lead exposure higher among underprivileged people (Baghurst, Tong et al. 
1999, Tyrrell, Melzer et al. 2013). One of the types of products that may contain 
lead and are still available are cosmetics. Kohl, widely used in Arabic countries, 
has previously been found to contain lead (Al-Ashban, Aslam et al. 2004, 
Haider, Abul Fazal Mohammed Yusuf, Lubna et al. 2012). Moreover, this heavy 
metal was also found in lipstick (Hepp, Mindak et al. 2009). Cheap jewellery, 
very often imported from low cost countries (LCC), has also been found to carry 
a risk of having a very high lead content, which has previously led to cases of 
acute lead poisoning when small parts were accidentally ingested by children 
(Maas, Patch et al. 2005, Weidenhamer, Clement 2007). Other products found 
to have lead as one their ingredients include stained glass (Landrigan, Tamblyn 
et al. 1980), ammunition (Tsuji, Wainman et al. 2008), fishing sinkers 
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(Scheuhammer, Norris 1996), toys (Weidenhamer 2009), candy wrappers (Kim, 
Park et al. 2008) and candles (Wasson, Guo et al. 2002).  
 While exposure to environmental lead poses a risk to human 
health that is mainly of a long-term, chronic type, occupational exposure can 
have a more acute effect leading to lead poisoning (Fu, Boffetta 1995, Fonte, 
Agosti et al. 2007). While metal smelting and battery production are the 
occupations with the highest risk of lead exposure, there are other employment 
types that, sometimes surprisingly, put people at an elevated risk of lead 
exposure, such as welding, scaffolding, roofing or crystal carving (Sen, Wolfson 
et al. 2002, Li, Zhang et al. 2004).  
 
Figure 1.3. The breakdown of male lead workers under medical surveillance in 2012/13 
by industrial sector 
Taken from http://www.hse.gov.uk/statistics/causdis/lead/lead.pdf accessed on 31/08/14 
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While there are considerable efforts to reduce the chances of people 
being exposed to lead by running public awareness campaigns and amending 
the standards and regulations for lead, lead has been reported by WHO to 
contribute to over 600 000 new cases of children developing cognitive 
impairment each year and 143 000 fatal cases per year, most of which occur in 
developing regions. While introduction of regulations controlling lead usage and 
exposure has been generally successful, as exemplified by blood lead levels 
(BLL) or surveillance of UK lead workers (Fig. 1.4.), lead standards are still a 
matter of controversy and are being debated due to a lack of clear and definitive 
data on ‘safe’ exposure levels (World Health Organization 2011, EFSA Panel 
on Contaminants in the Food Chain 2010, Schwartz, Hu 2007).  
 
 
Figure 1.4. The breakdown of male lead workers under medical surveillance since 
1996/97 with elevated blood-lead levels  
Taken from http://www.hse.gov.uk/statistics/causdis/lead/lead.pdf accessed on 31/08/14 
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1.1.3 Lead in the body 
What is the fate of lead once it enters the human body? 
Organic lead is readily absorbed by the human body. Absorption of 
organolead species is ca. 80% when inhaled and ingested organic lead is 
absorbed even more readily (Yu, Tsunoda et al. 2011). Inorganic lead is less 
readily absorbed when ingested, with only 5-15% absorption, whereas up to 
95% of lead inhaled as submicron particles is transferred to the bloodstream 
(Hursh, Schraub et al. 1969). After entering the bloodstream, lead is distributed 
among all the tissues. Initially, (Rabinowitz, Wetherill et al. 1976) proposed a 
three compartmental model to describe the disposition of lead inside the body. 
Blood itself (mainly red blood cells) was described as the first compartment, in 
which the half-life of lead is around 35 days. The second compartment consists 
of soft tissues with lead half-life of 40 days. Last, and the most important 
compartment, is mineralizing tissue which accumulates lead that can stay 
incorporated in it for decades. Currently however, the recognised model of lead 
distribution involves two compartments and classifies blood together with soft 
tissues as the first compartment and mineralising tissue as the second one 
(EFSA Panel on Contaminants in the Food Chain 2010). The latter can be 
further sub-divided into cortical bone and trabecular bone (Brito, McNeill et al. 
2005). It has been estimated that lead accumulated in teeth and bones 
accounts for ca. 95% of body lead burden with more than 70% of it being 
localized to dense bone (Barry, Mossman 1970). 
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The half-life of lead in human bone tissue can range from 10 to 30 years 
(Rabinowitz 1991). Due to the fact that lead can be slowly released from bones, 
a long time after initial exposure, mineralizing tissue can be regarded as a 
possible endogenous source of lead. The rate at which this heavy metal is 
transferred back into the bloodstream depends on the rate of bone metabolism. 
While this rate is known to differ, depending on type of bone (compact with a 
slow turnover or trabecular with a fast turnover), there are also other factors, 
normally affecting calcium release from bone, which can cause an increase of 
the rate at which lead is mobilised from this tissue. These include pregnancy, 
lactation, menopause and age-related bone loss (Silbergeld, Schwartz et al. 
1988, Silbergeld 1991).  
 Due to relatively fast lead removal rates, blood lead levels can be 
used as an indication of recent exposure to this heavy metal. Bone tissue levels 
can be reliably used to infer cumulative, long term lead exposure due to 
persistence of this metal in mineralizing tissues. Bone lead can be particularly 
useful for investigation of delayed lead toxicity as well as the relationship 
between age-related diseases and chronic lead exposure (Hu 1998, Hu, 
Rabinowitz et al. 1998).  
 Lead is neurotoxic, particularly during development. The exact 
mechanism that allows lead to cross the blood brain barrier (BBB) is not fully 
understood. However, there are two mechanisms that have been proposed as 
possible explanations for lead entry into the brain. The first is based on the 
observation that lead substitutes for calcium in cellular milieu (Marchetti 2003). 
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It is plausible that lead gains entry into the brain using store-operated cation 
channels which are normally used by calcium ions. Kerper and co-workers 
(1997) have shown that depletion of intracellular calcium caused an influx of 
lead into brain capillary endothelial cells which suggests that, indeed, lead 
might be taken up by the cells via the same mechanism as calcium. While lead 
has been reported to enter voltage-gated calcium channels in bovine adrenal 
medullary cells (Simons, Pocock 1987) and transport via anion exchange was 
shown in human red blood cells (Simons 1986), both of these mechanisms are 
highly unlikely to play a role in lead transport across the BBB due to the fact 
that voltage-gated calcium channels are absent from endothelial cells in 
capillaries of this organ and passive transport was claimed to be of questionable 
significance due to active pumping of lead back into capillaries by calcium-ATP-
dependent pump (Deane, Bradbury 1990).  
A second possibility (the two proposed mechanisms are not mutually 
exclusive and may act in synergy to allow lead to cross the BBB) involves 
disruption of blood barriers by lead. It has previously been shown that lead has 
the potential to alter the permeability of the blood-cerebrospinal fluid barrier 
(BCB) by changing the levels of claudin-1, a major constituent of tight junctions 
(Shi, Zheng 2007). However, experiments have shown that this phenomenon 
occurs only prior to the formation of a tight barrier. In the case of the mature 
barrier, lead was shown not to have any effect on its tightness. The integrity of 
both, BBB and BCB, is dependent on tight junctions between the cells that they 
are composed of, which suggests that the BBB could be affected by lead in a 
manner similar to the BCB. Investigation in adult rats revealed that also in 
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animals with mature BBB, exposure to lead causes leakage of microvessels but 
in this case a different mechanism was suggested to be responsible for altered 
permeabilization (Strużyńska, Walski et al. 1997). The authors proposed 
altered lipid composition of cellular membranes in response to lead as one of 
the possible mechanisms inducing disruption of the BBB. More recently, Wang 
and co-workers (2007) have also suggested a possible role played by occludin, 
another protein which, like claudin-1, is also a component of tight junctions and 
expression of which decreases upon exposure to lead.  
The fate of lead inside the brain is also not fully understood. However, it 
has been proposed that there is no difference in terms of uptake of this heavy 
metal among different brain regions (Widzowski, Cory-Slechta 1994). It seems 
likely that varied response to lead among different parts of the brain is due to 
their intrinsic susceptibility to the insult rather than differences in the 
concentration of this metal.  
While on the macroscopic level the distribution of lead in the brain seems 
to be homogenous, on a microscopic level the accumulation patterns of lead 
appear to be different. It has been shown in different cellular and animal models 
that astroglia take up this heavy metal more readily than neuronal cells (Tiffany-
Castiglioni, Qian 2001, Holtzman, DeVries et al. 1984). Moreover, it seems that 
cellular differentiation level also has an impact on lead assimilation (Lindahl, 
Bird et al. 1999).  
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Figure 1.5. Lead accumulation, storage, release, and neurotoxicity in astroglia.  
This diagram depicts the following events: (1) entry of Pb2+ ions into the cell by one or more 
mechanisms; (2) possible binding of Pb2+ by metalloregulatory proteins as well as by the Ca2+-
regulated ER chaperone GRP78 (3); (4) mineralization and storage of the Pb2+ in lysosomes 
and possibly other organelles such as mitochondria (5) and nucleus (6); (7) efflux of Pb2+ from 
the cell by one or more mechanisms, such as a putative Pb2+–ATPase or a Ca2+–ATPase; (8) 
disruption of Ca2+ homeostasis by numerous mechanisms. Diagram and legend adapted from 
(Tiffany-Castiglioni, Qian 2001).  
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While the whole body distribution of lead differs depending on the tissue 
type as well as time after exposure, the localization of this heavy metal within 
the cell seems to be much more specific. The vast majority of research 
performed on lead distribution within the cell, which dates back to as early as 
1960s, shows that its primary target is mitochondrion. In 1969 Castellino and 
Aloj examined distribution of lead in rat kidney and liver homogenates showing 
that the heavy metal has a high affinity for mitochondria. Moreover, a number 
of washes performed to examine the strength of this interaction did not have a 
significant impact on the binding of the heavy metal to mitochondria as indicated 
by no loss of radioactive signal (1969).  Barltrop and co-workers (1971) also 
reported that in all of the different rat tissues they analysed, including liver, 
kidney and spleen, 203Pb used in the experiment was found mainly in the 
mitochondrial fraction with much less of the radioisotope bound to the 
lysosomal fraction.  Further experiments suggested that lead can bind to the 
inner as well as outer mitochondrial membrane (Oskarsson, Fowler 1985) and 
its direct role in targeting the permeability transition pore to induce apoptosis in 
rod photoreceptor cells has been suggested by He and co-workers (2000). 
However, there is one type of cells that seems to be an exception from the 
mitochondrial rule. Astroglia have been shown to sequester lead away from 
their mitochondria, in cytoplasmic inclusion bodies (Shirabe, Hirano 1977). 
Holtzman and co-workers (1984) used X-ray diffraction microanalysis to 
propose that the preferential accumulation of lead in astroglia, rather than 
neurons, is specific to mature rat brains and prevents lead-induced 
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encelopathy. The group has shown that lead can be detected in the cytoplasm 
as well as different organelles and nuclei of cells (neuronal, endothelial as well 
as astroglia) in encelopathic tissue while in the cells of pathology-free rats lead 
was primarily localised to cytoplasmic, lysosomal and nuclear foci in astroglia, 
keeping the heavy metal away from mitochondria. This observation was further 
confirmed in vitro (Holtzman, Olson et al. 1987) implying a vital role of 
mitochondria in lead toxicity and intracellular targets of the heavy metal. 
 
 
1.1.4 Lead as a neurotoxicant 
Lead has long been known to have a profound effect on the central 
nervous system (Damstra 1977). The two most important factors determining 
the severity of this effect, which will be discussed later, are dose / level of 
exposure and age. Other factors that affect the ability of the body to respond to 
lead insult include diet and genetic predisposition. Due to the natural ability of 
lead to mimic calcium, dietary calcium intake has been shown not only to affect 
gastrointestinal absorption of the heavy metal in humans (Blake, Mann 1983, 
Mahaffey 1974), but it has also been suggested to prevent lead-induced 
oxidative damage in the brain when administered as a supplement in drinking 
water to mice (Prasanthi, Devi et al. 2010). Another dietary factor which has the 
potential to affect lead toxicity is iron. Iron supplementation reduced lead-
induced disruption of the BBB in rats (Wang, Luo et al. 2007), probably via 
alteration of expression of occludin, which is particularly highly expressed in 
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endothelial cells of the brain (Hirase, Staddon et al. 1997). Wasserman and co-
workers (1994) have also proposed that iron supplementation has an positive 
impact on cognition in lead-exposed children, which has been further explored 
by Ruff and co-workers (1996) who showed that in two-year-olds with iron 
deficiency, lead persisted in blood for longer periods of time which correlates 
with lower cognitive function (however, in this case, a direct role of iron in 
oxygenation of neural tissue and, hence, impact on cognitive performance 
cannot be excluded). While different vitamins (such as E, C or B6) as well as 
other nutrients, such as selenium, have been hypothesised to alter the effect of 
lead on the body, including brain, most of these effects have been shown in 
animal experiments only, and further investigations are required to obtain more 
conclusive data on their role in prevention of lead neurotoxicity in humans (Hsu, 
Guo 2002).  
Genetic factors that play a role in susceptibility to lead-induced toxicity 
affect various aspects of lead biology such as its uptake, distribution, 
elimination as well as its detoxification and the ability of the cell to counteract 
the insult. Among various genetic factors which have been suggested to play a 
role in cellular responses to lead, variations in δ-aminolevulinic acid 
dehydratase (ALAD), glutathione-S-transferases (GSTs), hemochromatosis 
gene (HFE), metallothioneins (MTs) and the vitamin D receptor (VDR) have 
been proposed as plausible determinants of susceptibility to lead (Gundacker, 
Gencik et al. 2010, Kim, Lee et al. 2014). Figure 1-8 depicts a list of potential 
susceptibility genes.  
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Figure 1.6. Genes suggested to play a role in determining susceptibility to lead toxicity.  
VDR: citamin D receptor, DMT1: divalent metal transporter 1, HFE: hemochromatosis, ALAD: 
δ-aminolevulinic acid dehydratase, GCL: glutamyl-cysteine-ligase, GS: GSH synthetase, GR: 
GSH reductase, GPx: GSH peroxidase, GGT: gamma-glutamyl-transferase, GST: glutathione-
S-transferase, MT: metalliothionein, MRP2: multidrug resistance associated protein 2. Adapted 
from (Gundacker, Gencik et al. 2010) 
 
However, the most important factors which determine which organs will 
be affected by lead and how severe the damage will be are dose of lead and 
age of the exposed person.  
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As mentioned above, high doses of lead cause lead poisoning. Such an 
acute exposure to lead, usually of an occupational kind, is characterised by 
effects including abdominal pain, vomiting, muscle weakness, lethargy as well 
as encephalopathy (more prevalent in children) causing seizures, delirium and, 
in extreme cases, coma and death (Whitfield, Ch'ien et al. 1972). Chelation 
therapy has been in use for decades as an immediate treatment for lead 
poisoning (Bessman, Rubin et al. 1954, Cao, Skaug et al. 2014). Low dose or 
chronic exposure to lead causes a range of different effects which differ in their 
severity and include irritability, cognitive dysfunction, behavioural 
abnormalities, loss of appetite, weight loss, anaemia, headaches, subfertility, 
mild abdominal pain, reduced sensations, motor peripheral neuropathy 
characterised by foot / wrist drop and has also been suggested as a neurotoxic 
factor that could contribute to development of neurodegenerative disorders 
such as Alzheimer’s disease, Parkinson’s disease (Mendiola, Moreno et al. 
2011, Patil, Bhagwat et al. 2006, Araki, Honma et al. 1980, Landrigan 1989, 
Bihaqi, Huang et al. 2011).  
 The age at which exposure to lead occurs has a particularly high 
impact on the health outcome. As mentioned before, infants and children are at 
a particularly high risk due to the increased vulnerability of the developing 
neuronal system and to their natural hand-to-mouth behaviours as well as pica, 
a condition which mainly affects children and dramatically elevates the 
probability of ingestion of toxicants, such as lead (Madden, Russo et al. 1981). 
While there are recommendations for action, such as chelation therapy, when 
blood lead levels in children exceed a certain level, there is a general 
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consensus that there are no ‘safe’ blood lead concentrations. The US Centres 
for Disease Control and Prevention established in 1991 that 10 micrograms per 
decilitre is the ‘blood lead level of concern’, but this has been re-evaluated and 
lowered to 5 micrograms per decilitre following publication of studies which 
revealed that sub-10 μg/dL exposure still carries an increased risk of intellectual 
impairment (Canfield, Henderson Jr et al. 2003), violence and antisocial 
behaviour (Bellinger 2008). It is no longer referred to as a level of concern, 
rather a as a reference value, above which case management of the child 
should be considered. Ongoing research and epidemiological studies, as well 
as advances in terms of the ease of blood lead level detection have resulted in 
a case being made that the US reference level for blood lead should be reduced 
even further (Gilbert, Weiss 2006)., Both The Joint FAO/WHO Expert 
Committee on Food Additives (JECFA) and the European Food Safety 
Authority (EFSA) have concluded that it is not possible to establish a tolerable 
intake of lead, at any level, as no threshold could be identified for its effect on 
IQ in children.  
While acute exposure to lead causes very drastic health effects in adults, 
as mentioned earlier, it has also been suggested that chronic lifetime exposure 
to lead is linked to neurodegeneration (Stewart, Schwartz et al. 2006). Early life 
exposure of non-human primates to Pb2+ leads to Alzheimer-like effects in 
adulthood (Bihaqi, Huang et al. 2011). There is also an association between 
chronic Pb exposure and risk of Parkinson’sDisease (PD). Epidemiologic 
studies looking at chronic lifetime exposure to lead found over a two-fold 
increase in the risk of development of Parkinson’s disease in people with high 
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lead concentration in their long bones, rising to a three-fold increase in risk in 
people with the highest tibia lead content (Coon, Stark et al. 2006, Weisskopf, 
Weuve et al. 2010). While the study conducted by Coon and co-workers 
showed a significant association between tibia lead levels and PD only in the 
highest quartile of lifetime exposure, Weisskopf and co-workers looked at a 
considerably larger cohort of PD patients and further confirmed the association 
in individuals exposed via environmental, domestic and occupational routes. 
While lead seems to be a contributing factor to PD development, it has to be 
noted that it is not a direct and sole cause of the disease but rather one of many 
risk factors and requires further investigation to establish the strength of the 
correlation. Moreover, while it is possible to assess lead exposure due its long 
half-life in cortical bone, it cannot be ruled out that people with high lifetime lead 
exposure were also exposed to high levels of other metals and toxicants due to 
their occupation or living in an urban area.  
However, to date, the exact mechanisms mediating these delayed 
responses have not been fully elucidated and there are a number of possibilities 
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Figure 1.7. Effects of inorganic lead on children and adults (lowest observable adverse-
effect levels). Adapted from (Staudinger, Roth 1998) 
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1.1.5 Known mechanisms of lead action 
While there is a wide appreciation of the fact that lead has extremely 
negative health outcomes, the exact mechanisms by which this heavy metal 
exerts its toxic effects remain only partially understood. Moreover, it seems that 
different mechanisms of action exist in different tissues and the current level of 
understanding of lead toxicity varies, depending on which organ, or even cell 
type, is being considered. However, two main, general mechanisms have been 
proposed to explain how lead disrupts cellular homeostasis. The first 
mechanism involves excessive generation of reactive oxygen species (ROS) 
while the second one focuses on ionic mimicry and the ability of lead to 
substitute for ions, such as calcium and essential trace metals, such as zinc 
(Flora, Saxena et al. 2007, Simons 1993, Farmand, Ehdaie et al. 2005).  
Lead has been shown to induce oxidative stress in the form of ROS in a 
variety of tissues such as kidneys, liver and blood (Patra, Swarup et al. 2001, 
Khan, Qayyum et al. 2008, Gurer-Orhan, Sabır et al. 2004, Paul, Ghosh et al. 
2013). Brain specific oxidative damage linked to developmental lead exposure 
has been shown in mice (Wang, Wu et al. 2006) and rats (Bolin, Basha et al. 
2006). There is no evidence however, on whether neuronal damage induced 
by adult chronic exposure to this heavy metal is due to an increased production 
of ROS. In contrast to what has been observed in developmentally-exposed 
rodents, He and co-workers (2000) have shown that Pb2+ can induce apoptosis 
in retina of adult rats by directly binding to the mitochondrial permeability 
transition pore with no oxidative stress induction. Those differences suggest 
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that the mechanism of lead induced cell death may vary depending on the 
developmental stage of the organism or the cell type. 
 
Lead has been previously shown to cause an increase of cytoplasmic 
calcium concentration ([Ca2+]c) in platelets (Dowd, Gupta 1991) and Ca2+ 
release from the endoplasmic reticulum in hippocampal neurons (Fan, Zhou et 
al. 2013). Whether the mechanism of lead-induced dopaminergic cell 
neurotoxicity, such as occurs in PD, involves disruption of calcium homeostasis 
has yet to be elucidated. Interestingly, accumulation of mitochondrial calcium 
has been previously shown to play a role in the familial form of PD (Gandhi, 
Wood-Kaczmar et al. 2009). While mitochondria have calcium buffering 
properties (Werth, Thayer 1994), a significant rise in cellular Ca2+  levels can 
lead to mitochondrial calcium overload triggering apoptosis via different routes 
such as direct interaction with the mitochondrial permeability transition pore 
(MPTP; (Ichas, Mazat 1998) or induction of mitochondrial fission (Kaddour-
Djebbar, Choudhary et al. 2010). Indeed, the caspase 8 cleavage product of 
BAP31, an integral membrane protein of the endoplasmic reticulum (ER), 
induces mitochondrial fission through endoplasmic reticulum calcium signals. 
This enhances cytochrome c release and cell death (Breckenridge, D. G et al. 
2003). Moreover, calcium (Ojuka, Jones et al. 2003) as well as ROS (Sano, 
Fukuda 2008), have both been shown to regulate mitochondrial biogenesis by 
activating PGC1α, a transcriptional co-activator, which interacts with a number 
41 | P a g e  
 
of transcription factors (e.g. NRF-1 NRF-2, TFAM) leading to an increase in 
mitochondrial mass. 
  
 
Figure 1.8. Known intracellular effects and targets of lead. (1) Pb2+ is known to bind 
to various enzymes, such as ALAD, and alter their function; (2) Pb2+ has been reported to cause 
increased generation of ROS; (3) Binding of Pb2+ to mitochondrial PTP and its subsequent 
opening has been reported to induce apoptosis of rod photoreceptiors; (4) Binding of Pb2+ to 
glutathione has been suggested to alter antioxidant capacity of cells leading to increased 
oxidative damage; (5) Pb2+ has been shown to cause an increase of cytoplasmic calcium as 
well as release of the cation from its ER stores (6). 
 
The majority of mechanisms suggested as explanations for lead-induced 
cellular damage converge on mitochondria. The integrity of this organelle is 
particularly vital in the context of neurodegeneration due to the high-energy 
demand of neurons. Neuronal cells (especially dopaminergic neurons) pose an 
exceptional challenge in terms of their energy needs due to their unusually long 
42 | P a g e  
 
axons leading to high energy demands at very distal parts of the cell (Pissadaki, 
Bolam 2013). This generates a need for tight regulation of mitochondrial 
biogenesis, function and dynamics in those cells. Disruption of any of those 
processes can lead to neurodegeneration (Detmer, Chan 2007) which has been 
exemplified by disorders such as PD (Abou-Sleiman, Muqit et al. 2006), 
Alzheimer’s Disease (O'Donnell, Lulla et al. 2014) and Huntington’s disease 
(Kim, Moody et al. 2010). In the context of mitochondrial homeostasis PGC1α, 
a transcriptional co-activator, a master regulator of mitochondrial biogenesis 
and function, has to be mentioned. It controls the expression of nuclear 
respiratory factors 1 and 2 (NRF1 and NRF2), which are vital for transcription 
of numerous mitochondrial genes. PGC1α has been shown to respond to 
various physiological stimuli during periods of metabolic stress as well as 
oxidative stress. It has previously been implicated in the pathogenesis of PD 
(Shin, Ko et al. 2011) and a potentially protective role has been suggested 
(Zheng, Liao et al. 2010).  
 
1.2 Mitochondria 
1.2.1 Mitochondria – an overview  
While mitochondria are known for their crucial and primary role in cellular 
metabolism and generation of energy in the form of ATP, they are also involved 
in a variety of other cellular processes and signalling pathways as well as being 
one of the key regulators of programmed cell death. What distinguishes them 
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from other cellular organelles is the fact that they possess their own genetic 
material in the form of a double-stranded circular DNA molecule known as 
mitochondrial DNA (mtDNA). Human mtDNA is 16.5 kb long (Holt, Reyes 
2012), contains 13 protein-coding genes which are involved in electron 
transport and oxidative phosphorylation as well as 22 tRNA and 2 ribosomal 
RNA genes (12s and 16s). Moreover, recent studies have shown that a short, 
24 amino acid peptide, named humanin, is encoded within the 16s rRNA gene, 
by a 75 base pair (bp) open reading frame (ORF) (Hashimoto, Ito et al. 2001). 
It is believed that together with ROS, calcium and cytochrome c, humanin is 
involved in retrograde signalling, a process which enables communication 
between mitochondria and other cellular compartments.  
1.2.2 Mitochondria in energy production and apoptosis 
The primary function of mitochondria is generation of energy in the form 
of ATP in a process called oxidative phosphorylation. A number of protein 
complexes localised to inner mitochondrial membrane, comprising the electron 
transport chain,  conduct a series of redox reactions in which electrons are 
removed from NADH and succinate (electron donors) and are passed on to 
electron acceptors, such as oxygen. Complexes I (NADH Dehydrogenase), III 
(Ubiquinol cytochrome C oxidoreductase) and IV (Cytochrome C oxidase) 
transport protons in an active way (using energy supplied by electrons moving 
though ETC) from the mitochondrial matrix into the intermembrane space 
creating proton gradient which is subsequently used by complex V (ATP 
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synthase), which channels protons back to the matrix, to produce ATP using 
ADP and inorganic phosphate.  
Secondary role of mitochondria, which is tightly coupled with their 
primary function, is regulation of apoptosis. It is estimated that ca. 1-2% of 
oxygen used for respiration is ultimately converted to superoxide due to 
electron leak (Orrenius, Gogvadze et al. 2007). The main sites of O2• generation 
are complexes I and III with complex II playing a less of a role in mitochondrial 
ROS production (Koopman, Nijtmans et al. 2010, Turrens 2003). Mitochondrial 
ROS target a number of proteins including components of the ETC (Kokoszka, 
Coskun et al. 2001). While oxidation of ETC subunits decreases energy 
production, oxidative damage that affects thiol groups of mitochondrial 
components can sensitise permeability transition pore to opening triggered by 
calcium (discussed below). Lead has been previously shown to induce 
oxidative damage in brain tissue (Wang, Wu et al. 2006, Bolin, Basha et al. 
2006) as well as being capable of targeting mitochondria, PTP in particular, 
leading to apoptosis induction in rod photoreceptor cells (He, Poblenz et al. 
2000) suggesting that the mechanism of its neurotoxicity relies of this organelle.  
Apart from its role in energy production, the electrical potential of 
mitochondria also has a function in uptake of calcium ions by this organelle 
(Rottenberg, Scarpa 1974, Scarpa, Graziotti 1973). Excessive transport of Ca2+ 
into mitochondria has the potential to induce opening of permeability transition 
pore and subsequent release of calcium as well as dissipation of proton 
gradient which leads to inhibition of ATP production (Maciel, Vercesi et al. 
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2001). Moreover, increased cytoplasmic calcium levels can also trigger calpain-
mediated cleavage of apoptosis inducing factor (AIF) as well as Bid. Truncated 
Bid causes oligomerisation of Bax which produces a lipidic pore at the outer 
membrane of mitochondria which facilitates release of intermembrane proteins 
such as cytochrome c and AIF leading to activation of caspase dependent and 
caspase independent cell death, respectively. As a consequence of its ability to 
mimic calcium and interact with calcium-dependent proteins, lead has an 
intrinsic potential to disrupt mitochondrial function via interference with Ca2+ 
pathways in addition to a potential direct interaction with the organelle.  
 
 
 
Figure 1.9. Structure of mitochondria. 
Taken from http://www.bio.uni-kl.de/en/pflanzenphysiologie/forschung/agn-research-mcf/ 
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1.2.3 Mitochondrial biogenesis 
Different types of cells in different tissues have their own unique energy 
requirements which dictate how large and complex their mitochondrial network 
is. Cells in the human body range from ones that have no mitochondria, 
exemplified by red blood cells, to cells that contain a very high number of those 
organelles, e.g. the oocyte, which is estimated to have between 100 000 to 10 
000 000 mitochondria (Ankel-Simons, Cummins 1996). Moreover, cells have 
an intrinsic flexibility regarding their mitochondrial mass and can respond to 
changing energy requirements by modification of their rate of mitochondrial 
biogenesis. Muscle cells are an excellent example of how an extended period 
of an exposure to a stimulus, such as endurance exercise can not only boost 
their respiratory capacity but also lead to an increase of the total mitochondrial 
mass (Holloszy, Coyle 1984). The process of mitochondrial biogenesis is 
regulated by peroxisome proliferator activated receptor gamma co-activator 1 
alpha (PGC1α; (Hood 2009).  
PGC1α was discovered by Bruce Spiegelman’s laboratory working on 
adaptive thermogenesis (Puigserver, Wu et al. 1998), who showed that 
retroviral overexpression of PGC1α in white fat cells led to a doubling of their 
mitochondrial content. Further research revealed that PGC1α exerts its effect 
on the expression of various mitochondrial proteins as well as factors involved 
in antioxidant responses via interaction with a number of transcription factors. 
The key targets of PGC1α include the estrogen related receptor α (ERRα; 
(Schreiber, Emter et al. 2004) as well as NRF1 and 2. While NRF 1 and 2 induce 
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the expression of some of the mitochondrial proteins, they also control the 
expression of mitochondrial transcription factor (TFAM), which has a 
mitochondrial targeting sequence (Parisi, Clayton 1991) and is responsible for 
transcription of genes from mtDNA (Shi, Dierckx et al. 2012) as well as the 
expression and maintenance of mtDNA (Kang, Kim et al. 2007, Ekstrand, 
Falkenberg et al. 2004) which implies that PGC1α is a unique factor mediating 
nuclear regulatory phenomena and control of mitochondrial transcription 
machinery. Expression and activity of PGC1α itself has been shown to be 
regulated by a plethora of factors including exercise-induced calcium signals 
acting via Ca2+/calmodulin-dependent protein kinase (Wu, Kanatous et al. 
2002), nitric oxide (Nisoli, Clementi et al. 2003), cAMP elevated in response to 
cold or fasting as well as AMPK (Puigserver, Wu et al. 1998). Induction of 
PGC1α expression is followed by an increase in mitochondrial mass as well as 
increased respiration and ATP production which implies functional role of the 
newly produced mitochondria (Nisoli, Falcone et al. 2004).  
NRF-1 is a nuclear respiratory factor which binds to promoters of a 
number of nuclear genes coding for proteins involved in respiration such as 
TFAM, ATP synthase gamma-subunit gene and subunits of the cytochrome 
oxidase and reductase complexes (Chau, Evans et al. 1992, Virbasius, 
Scarpulla 1994). Very importantly, NRF-1 drives the expression of both 
isoforms of mitochondrial transcription specificity factors (TFB) which are 
known to enhance mtDNA transcription driven by TFAM (Gleyzer, Vercauteren 
et al. 2005). Another process which is indirectly regulated by NRF-1 is import 
of proteins into mitochondria. A multiprotein complex localised to outer 
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mitochondrial membrane (TOM) is responsible for orchestrating the import of 
all the vital components required for correct functioning of this organelle. 
Expression of TOMM20 which is one of the key components of the complex has 
been shown to be tightly regulated not only by NRF-2, but also by NRF-1 
working in synergy with each other (Blesa, Prieto-Ruiz et al. 2007). Both NRF-
1 and TFAM were previously shown to be upregulated under conditions 
inducing mtDNA damage, supposedly as an attempt to rescue the cells from a 
possible energy deficit (Hickson-Bick, Jones et al. 2008). Interestingly, both 
proteins are also upregulated in muscle cells of elderly people possibly to 
compensate for an age-related decline in energy production (Lezza, Pesce et 
al. 2001).  
NRF2 on the other hand is known to be involved in regulation of 
expression of a number of subunits of cytochrome oxidase (Ongwijitwat, Wong-
Riley 2005). NRF2 silencing experiments showed that all of the nuclear genes 
encoding COX subunits were significantly less expressed as a result of the 
knockdown (Ongwijitwat, Liang et al. 2006). In addition to COX regulation, 
NRF2 binding sites have been identified in the promoters of a number of 
respiratory chain genes including TFAM as well as mitochondrial transcription 
factor B1 and B2 (Rantanen, Gaspari et al. 2003), encoding mitochondrial 
enzymes. While it is known that neuronal cells have particularly high energy 
requirements and healthy mitochondria are essential for their correct function, 
NRF2 as well as cytochrome oxidase were implicated in maintenance of 
neuronal activity which was also suggested to have a direct role in regulation of 
NRF2 expression itself (Guo, Nie et al. 2000).  
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The two main functions of TFAM, mentioned before, include regulation 
of transcription of mitochondrial genes as well as maintenance and replication 
of mtDNA (Ekstrand, Falkenberg et al. 2004, Virbasius, Scarpulla 1994, 
Gleyzer, Vercauteren et al. 2005). Larsson and co-workers have previously 
shown that heterozygous knockout of TFAM leads to low copy number of 
mtDNA as well as respiration impairment while homozygous knockout is 
embryonically lethal (1998). It has recently been estimated that there are ca. 
900 TFAM molecules bound to one mtDNA molecule (Takamatsu, Umeda et 
al. 2002). Such high occupancy of mtDNA by TFAM was found to be mainly 
associated with the light strand promoter of the circular DNA (which functions 
to initiate transcription of mtDNA) and has been proposed to indicate a state of 
constant transcription of mitochondrial genome when other mitochondrial 
transcription factors are present (Alam, Kanki et al. 2003). Such high 
abundance of TFAM on mtDNA and its presence in mtDNA-protein complexes 
forming the characteristic nucleoidal structure of mitochondria has been 
interpreted as an indication of its role in regulation of mtDNA stability and 
packaging (Kang, Kim et al. 2007).  
 Taken together, given the upstream role of PGC1α in regulation of 
NRF1, NRF2 as well as TFAM, it is clear how fundamental its function is to the 
maintenance of cellular energy homeostasis.  
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1.2.4 Mitochondrial dynamics 
Mitochondrial dynamics is a term used to describe the processes of 
structural changes that happen in the organelle and are a result of fusion and 
fission which allow mitochondria to function as either separate, independent 
units or form long, filamentous networks. While mitochondrial dynamics, fusion 
in particular, has an important role in the exchange of mitochondrial genetic 
material (Chen, McCaffery et al. 2007) which is required for their correct 
function, it also allows the organelle to be transported to distal parts of the cell, 
where the local energy requirement is particularly high, an example of which 
are neuronal synapses (Hollenbeck, Saxton 2005, Calkins, Manczak et al. 
2011). Moreover, it has also been proposed that fusion and fission processes 
allow for isolation of damaged, dysfunctional mitochondria and their subsequent 
removal from the cell by mitophagy (Twig, Elorza et al. 2008). 
 Both, fission and fusion, are driven by unique sets of proteins 
which drive the changes in mitochondrial morphology. Dynamin related protein 
1 (Drp1), a member of the dynamin family of GTPases, is the key player in 
mitochondrial fragmentation process. Its suggested mechanism of action, very 
similar to Dnm1p- (a yeast homologue of Drp1) driven fission in yeast, involves 
formation of helical polymers composed of Drp1 subunits, which undergo a 
structural change upon GTP hydrolysis leading to constriction of the 
mitochondrial membrane trapped inside the Drp1-polymer loop and subsequent 
fission (Mears, Lackner et al. 2011, Elgass, Pakay et al. 2013). However, as 
understanding of mitochondrial dynamics advanced, an appreciation of other 
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players involved in fragmentation of this organelle grew. These include fission 
protein 1 (Fis1;(Zhang, Chan 2007), mitochondrial fission factor (Mff; (Otera, 
Wang et al. 2010), mitochondrial dynamics proteins of 49 and 51 kDa (MiD49 
and MiD51; (Palmer, Osellame et al. 2011). All of these factors are believed to 
play a role in the recruitment of Drp1 to the mitochondrial membrane. 
Nevertheless, it has been very difficult to establish how important each one of 
these proteins is for the fission process due to the fact that functional 
redundancy has been shown in vitro (Loson, Song et al. 2013). Also, very 
interestingly, contrasting results were obtained in some studies, for example 
following knockout, Fis1 was shown to be dispensable for mitochondrial fission 
(Otera, Wang et al. 2010) whereas silencing of this gene caused abnormal 
elongation of mitochondria and induction of profound morphological changes of 
this organelle, indicating that it is indeed indispensable for mitochondrial fission 
(Koch, Yoon et al. 2005). It is still unclear, but a possibility exists that, as 
suggested by Zhao and co-workers (2011), factors such as MiD51, which bind 
Drp1, may actually inhibit fission by physically interacting with Drp1 rather than 
promote it by recruiting Drp1 and allowing it to exert its normal function.  
The process of mitochondrial fusion is more complex than that of fission 
due to the requirement for correct joining of inner and outer mitochondrial 
membranes (IMM and OMM respectively) of adjacent organelles. There are 
three main fusion proteins, large GTPases that belong to the dynamin family, 
which mediate mitochondrial fusion. Mitofusin 1 and mitofusin 2 (Mfn1 and Mfn2 
respectively) are both vital for fusion of the outer mitochondrial membrane (IMM 
fusion requires Opa1). While dysfunction of either one of these proteins has 
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been shown to cause mitochondrial fragmentation, it has also been noted that 
the morphology of the fragmented mitochondria varies between the mutants 
(Chen, Detmer et al. 2003). Moreover, it has been shown that mitofusins act in 
trans and their presence is required on the outer membrane of both 
mitochondria, rather than just one, to lead to a successful fusion event 
(Koshiba, Detmer et al. 2004). Koshiba and co-workers have also shown that 
prior to the actual merger of the OMM, a tethering step, also mediated by 
mitofusins is required and is driven by one of the hydrophobic heptad repeats 
(HR2) present in both of the proteins.  
Inner membrane fusion occurs separately from the events taking place 
at the OMM and is known to be a mechanistically distinct process (Malka, 
Guillery et al. 2005). While fusion of both, OMM and IMM, require GTP 
hydrolysis, fusion of IMM is also highly reliant on mitochondrial membrane 
potential (Meeusen, McCaffery et al. 2004). Optic atrophy 1 (Opa1) is the key 
protein controlling IMM fusion. Opa1, which has eight isoforms in humans 
(Delettre, Griffoin et al. 2001), is imported into mitochondria and processed to 
its long form (L-Opa1) via removal of its mitochondrial localisation signal. Under 
normal, stress-free conditions, ca. 50% of L-Opa1 remains embedded in the 
IMM (Ishihara, Fujita et al. 2006) while the other half is further processed to a 
short form (S-Opa1), which lacks membrane anchorage, by Oma1 (Head, 
Griparic et al. 2009) and YME1L (Song, Chen et al. 2007). Ishihara and co-
workers (2006) showed in their elegant experiment that knockdown of Opa1 
leads to mitochondrial fragmentation which can be rescued by re-introduction 
of L-Opa1 but not S-Opa1. The experiment clearly suggests that it is the long, 
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membrane-bound form of the protein that is needed for mitochondrial fusion. 
Since it has been shown that fusion is highly dependent on mitochondrial 
membrane potential (Guillery, Malka et al. 2008), it comes as no surprise that 
mitochondrial depolarisation is one of the main factors that induce L-Opa-1 
processing and increased levels of the shorter form of the protein (Griparic, 
Kanazawa et al. 2007). 
 
 
Figure 1.10. Schematic representation of mitochondrial fission and fusion indicating the 
key player proteins in both processes 
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Figure 1.11. Functions of mitochondrial dynamics. The mitochondrial life cycle involves 
frequent cycles of fusion and fission that allow the cell to generate multiple heterogeneous 
mitochondria or interconnected mitochondrial networks, depending on the physiological 
conditions. B) Fusion and fission of mitochondria are important for many biological functions 
depicted in the figure above. Taken from (Westermann 2010) 
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1.2.5 Reactive oxygen species 
Reactive oxygen species (ROS) is a term encompassing a number of 
chemically reactive free radicals and molecules derived from oxygen, including 
superoxide anion (O2-•), singlet oxygen (1O2), hydrogen peroxide (H2O2), 
peroxide (•O2-2), hydroxyl radical (•HO) and hydroxyl ion (HO-). Endogenous 
intracellular ROS are produced within the cell as a normal by-product of various 
processes, in organelles such as peroxisomes, endoplasmic reticulum and 
mitochondria (which is the main source of these species). Leakage of electrons 
from different redox complexes during oxidative phosphorylation and 
subsequent reduction of oxygen lead to formation of superoxide anion, a 
common precursor of other ROS. While O2-• is a species which is confined to 
mitochondria, its generation site, dismutation of superoxide (either spontaneous 
or performed by superoxide dismutase enzyme (SOD)) into hydrogen peroxide 
produces a mobile species that can pass through membranes and accumulate 
in cytosol (Loschen, Azzi et al. 1974). While mitochondria are indeed the main 
site of ROS formation, with ca. 1-2% of oxygen being converted to O2-• (Turrens 
2003), there are other exogenous processes and factors, such as certain 
classes of carcinogen or interleukins, which also have the potential to induce 
ROS generation (Klaunig, Kamendulis et al. 2010).  
While ROS are potentially very dangerous agents capable of disrupting 
normal cellular function by inducing damage to important cellular components, 
cells are equipped with an intrinsic antioxidant defence system which allows 
them to deal with ROS without allowing disruption of homeostasis. The most 
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important players in this ROS scavenging network are antioxidants such as 
glutathione, bilirubin and vitamins C and E, and enzymes, which act to detoxify 
ROS and produce less harmful products. There are several different classes of 
enzyme that perform the above mentioned functions, which reside in specific 
cellular niches where they act on their particular substrates. The three main 
classes of antioxidant enzymes are the previously mentioned SODs (acting on 
superoxide anion), catalases (detoxifying H2O2) and various peroxidases, such 
as glutathione peroxidase, for most of which H2O2 is the main target.   
 
 
 
Figure 1.12. Biochemical reactions of reactive oxygen species. Formation and 
dismutation of ROS.  
 
 
For a long time people believed that ROS had no biological function 
within the cell. This view has changed upon discovery of the signalling potential 
that reactive oxygen species have. The concept of ROS acting as signalling 
molecules was received with a large dose of scepticism due to the fact that, 
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unlike most signalling molecules which interact with their specific targets on a 
macromolecular level, ROS act on an atomic level which is much less specific 
and could potentially target a wide spectrum of cellular components. While ROS 
have been discovered to have a direct effect on transcription factors as well as 
protein kinases and phosphatases (Sauer, Wartenberg et al. 2001, Byun, Son 
et al. 2014, Okoh, Felty et al. 2013) their effect on cellular signalling is also 
largely due their ability to induce changes in the structure of redox sensitive 
proteins. This protein group is characterised by being rich in cysteine residues 
which, in the presence of ROS, form disulfide bonds which cause either a 
conformational change (intra-molecular bridge formed) or a multimerisation of 
proteins (inter-molecular bridges). Following induction by ROS, redox-sensitive 
proteins gain the capacity to trigger cellular stress response by activation of a 
variety of stress signalling pathways. This process however, is largely 
dependent on the amount of ROS present in cellular milieu (Adler, Yin et al. 
1999).  
Since cells have an innate ability to detoxify ROS generated as a by-
product of normal cellular processes, oxidative stress has been defined as a 
state in which an imbalance occurs between generation of ROS and antioxidant 
defence mechanisms such that the ROS levels significantly exceed the capacity 
of the cell to neutralise them.  Loss of control over ROS levels creates a 
potential for induction of damage to proteins, lipids as well as nucleic acids 
within the cell. Depending on the extent of the damage, cells can either recover 
from it or undergo apoptosis if the oxidative stress exceeds a certain threshold. 
The level of oxidative damage of genomic DNA is much lower and can be 
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repaired much more efficiently than the damage done to mitochondrial DNA 
(Yakes, Van Houten 1997). Unsurprisingly, it is the mitochondria that are the 
primary decision maker regarding commitment to programmed cell death in 
response to extensive oxidative stress. High levels of ROS generated by this 
organelle trigger an auto-destructive loop in which further disruption of 
mitochondria promotes an even greater production of reactive oxygen species. 
An increase in mitochondrial ROS has been shown to precede loss of 
mitochondrial membrane potential (Sidoti-de Fraisse, Rincheval et al. 1998) 
and ROS have been shown to induce apoptosis via a caspase-independent 
route (Carmody, Cotter 2000) as well as by a caspase-mediated mechanism 
(Oh, Lim 2006, Garcia-Ruiz, Colell et al. 2000, Hampton, Orrenius 1997) via 
mitochondrial membrane permeability transition and release of cytochrome c. 
Interestingly, Hampton and Orrenius (1997) as well as Guenal and co-workers 
(1997) have shown that while low levels of oxidative stress lead to induction of 
programmed cell death, high levels of ROS have the ability to either push the 
cell from apoptosis to necrosis or directly trigger necrotic cell death.  
 
1.2.6 Mitochondrial biogenesis and dynamics as antioxidant defence 
mechanisms 
While, as mentioned earlier, a plethora of ROS scavenging enzymes 
exist, which, together with endogenous antioxidants comprise the main cellular 
antioxidant system, changes in mitochondrial number as well as morphology 
can also help the cell to prevent or recover from oxidative damage. Research 
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conducted on cells exposed to oxidative stress showed that under such 
conditions there is an observable increase of mitochondrial mass, as well as an 
increase in the copy number of mitochondrial DNA (Lee, Yin et al. 2000, Lee, 
Yin et al. 2002). This phenomenon can be attributed to activity of PGC1α, which 
is known to be induced by ROS under stress conditions (Valle, Alvarez-
Barrientos et al. 2005, Spiegelman 2007), a mechanism which is particularly 
important in neuronal cells (St-Pierre, Drori et al. 2006). It has been suggested 
that replication of the mitochondrial genome as well as increased production of 
mitochondria are compensation mechanisms that help maintain a sufficient 
level of healthy mitochondria which would be able to sustain cellular energy 
needs in conditions when a large fraction of these organelles have suffered 
ROS-induced damage rendering them dysfunctional (Lee, Wei 2005, Chou, Yu 
et al. 2007, Yu 2011, Shen, Zhang et al. 2008).  
While the role of mitochondrial biogenesis in antioxidant defence is well 
established, the role of dynamics of this organelle is not as obvious and while 
it has previously been shown that excessive ROS generation can impact 
mitochondrial fission and fusion balance, both processes also play a role in 
cellular susceptibility to oxidative agents. Figure 1-14 highlights the main 
negative outcomes of non-physiological shift of fusion/fission balance in either 
direction.  
As mentioned before, fusion of mitochondria allows for exchange of 
mtDNA and maintenance of the integrity of the mitochondrial genome. Due to 
ongoing research in the field of mitochondrial genetics, these is now a wide 
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appreciation of phenomena such as heteroplasmy as well as 
microheteroplasmy (Smigrodzki, Khan 2005) which describe the existence of 
multiple mutations within the mtDNA of each cell which are independent of each 
other and result from inherited mutations as well as spontaneous germ line 
mutations and sporadic mutations acquired later on in life. However, due to the 
‘phenotypic threshold effect’, comprehensively reviewed by Rossignol and co-
workers (2003), which states that the phenotypic manifestation of mitochondrial 
impairment occurs only once the number of dysfunctional mitochondria 
exceeds a certain level, mitochondrial fusion plays an extremely important role 
in preventing the accumulation of damaged mitochondria, which would 
otherwise exacerbate ROS generation and oxidative damage, very often 
leading to cellular demise. Thus, balanced fusion helps to maintain a high 
dilution factor of mutated mtDNA and lowers the risk of biogenesis of 
dysfunctional mitochondria (Chen, Vermulst et al. 2010, Chen, McCaffery et al. 
2007, Sato, Nakada et al. 2009). Experiments involving liver-specific Mfn2 
knockout mice confirmed that loss of this fusion protein promotes accumulation 
of ROS (Sebastian, Hernandez-Alvarez et al. 2012) 
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Figure 1.13. Deleterious effects of an imbalance of mitochondrial fission and fusion. 
Adapted from (Seo, Joseph et al. 2010) 
 
In terms of ROS defence, fusion also prevents accumulation of damaged 
mitochondria, which contribute to oxidative stress (Lemasters 2005), by 
enabling removal of defective organelles by mitophagy (Youle, Narendra 2010, 
Frank, Duvezin-Caubet et al. 2012, Gomes, Scorrano 2008). While facilitation 
of mitophagy by mitochondrial fragmentation and a special role of Fis1 and Drp1 
in this process have been well-documented (Twig, Elorza et al. 2008) it still has 
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to be evaluated whether autophagocytic removal of mitochondria is actually 
fully dependent on fission in mammalian cells or whether it can take place in a 
fragmentation-independent manner, as previously reported in yeast (Mendl, 
Occhipinti et al. 2011). While fusion has its role in promotion of cellular health, 
it has to be maintained in balance with mitochondrial fission as the latter 
process is equally important for quality maintenance of this organelle. 
 
1.2.7 Mitochondria in neurodegeneration – Parkinson’s Disease 
Cells most susceptible to death stemming from oxidative stress and 
mitochondrial dysfunction are long-lived post-mitotic cells which have a reduced 
ability to regenerate, such as neurons. Due to that fact, the integrity of 
mitochondria is particularly important in the context of neurodegeneration 
because of the high-energy demand of neurons due to their unusually long 
axons and requirement for ATP generation in synaptic regions (Pissadaki, 
Bolam 2013). This requirement generates a need for tight regulation of 
mitochondrial biogenesis, function and dynamics in such cells. Disruption of any 
of these processes can ultimately lead to mitochondrial failure resulting in 
neurodegeneration (Detmer, Chan 2007) which is exemplified in disorders such 
as PD (Abou-Sleiman, Muqit et al. 2006), Alzheimer’s Disease (O'Donnell, Lulla 
et al. 2014) and Huntington’s disease (Kim, Moody et al. 2010). 
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Figure 1.14. Relationship between mitochondria, oxidative stress and apoptosis. Adapted 
from (Federico, Cardaioli et al. 2012) 
 
From a genetic point of view, mitochondriopathies of the neurological 
kind can be divided primarily into two categories, depending on whether the 
genes affected are coded by mitochondrial or nuclear DNA (nDNA). While 
mtDNA mutations can affect only tRNAs, rRNAs or respiratory chain proteins, 
nDNA mutations affect not only respiratory chain components but also proteins 
regulating mitochondrial function, dynamics as well as metabolism (Federico, 
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Cardaioli et al. 2012). The protein classes discussed above are also targets of 
neurotoxicants that contribute to neurodegeneration, such as the pesticide 
rotenone and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), which 
have been shown to inhibit complex I leading to development of PD symptoms 
(Betarbet, Sherer et al. 2000, Langston, Ballard et al. 1983).  
 Mitochondrial dysfunction has been thought to underlie the 
pathogenesis of PD since 1989 (Schapira, Cooper et al. 1989). Perturbed 
energy metabolism, leading to increased oxidative stress and generation of 
high levels of reactive oxygen species (ROS) in the mitochondria is thought to 
be a key pathological step (Gille, HUNG et al. 2004). One of the mechanisms 
believed to contribute to dopaminergic neuronal cell death is inhibition of 
mitochondrial complex I (Sherer, Richardson et al. 2007). This complex is the 
first component of the mitochondrial electron transport chain (ETC), the site of 
oxidative phosphorylation. While the ability to impair the function of NADH 
dehydrogenase is a common feature of toxicants known to induce PD and the 
inhibition of complex I by these compounds is a systemic effect, dopaminergic 
neurons found in the substantia nigra appear to be most severely affected and 
selectively degenerate. A possible explanation of this phenomenon is that DA 
neuronal cells display increased basal levels of reactive oxygen species (ROS) 
compared with other cells, resulting from metabolism of dopamine and auto-
oxidation. Inhibition of complex I would exacerbate this phenomenon, leading 
to cell-specific toxicity (Giasson, Lee 2000, Olanow, Tatton 1999).  
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However, recent work by Choi and co-workers (2011) suggests that in 
the case of rotenone, it may not be the inhibition of NADH dehydrogenase per 
se that is directly toxic to DA neurons but rather another mechanism which is 
potentiated by inhibition of that complex. Deletion of the gene encoding one of 
the NADH dehydrogenase subunits, Ndufs4, which renders this complex 
dysfunctional, was not sufficient to trigger degeneration of neurons. Moreover, 
no neuronal death was observed upon treatment with piericidin A, a complex I 
inhibitor. Other mechanisms which could mediate rotenone neurotoxicity were 
investigated. Microtubule disassembly followed by dopamine accumulation and 
subsequent ROS generation, was proposed to explain the effect of rotenone 
treatment. Two proteins, mutations in which underlie some familial forms of PD, 
parkin and α-synuclein, have also been identified as regulators of microtubule 
dynamics which further supports the role of microtubule dysregulation in 
rotenone toxicity (Yang, Jiang et al. 2005, Alim, Ma et al. 2004).  
Further evidence supporting a role of mitochondria in PD pathogenesis 
comes from a study which showed an increase in deletions of mitochondrial 
DNA (mtDNA) in the striatum of PD patients (Ikebe, Tanaka et al. 1990). The 
importance of mitochondrially encoded genes in the neurodegenerative 
disorder was confirmed by the creation of parkinsonian cybrids (cytoplasmic 
hybrids formed by fusion of enucleated cells from PD patients, in this case 
platelets, with ρ0 cells deprived of mtDNA by long term exposure to ethidium 
bromide) which displayed a reduction in the activity of complexes I and IV in 
comparison with age and gender matched controls (Esteves, Lu et al. 2010, 
Appukuttan, Varghese et al. 2011).  
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Recently, disruption of mitochondrial fission and fusion balance has 
been suggested as a novel mechanism underlying neurodegeneration in PD 
(Knott, Bossy‐Wetzel 2008). Such an event could lead to impaired energy 
production, increased oxidative stress, a loss of mtDNA as well as alterations 
in calcium homeostasis. PINK1 and Parkin are two proteins that are involved in 
the regulation of mitochondrial dynamics and mutations or alterations in these 
proteins in PD could possibly contribute to mitochondria-mediated 
neurodegeneration. This hypothesis is supported by the fact that decreased 
levels of Drp1 and Fis1 and increased expression of PINK1 in senescent cells 
confer oxidative stress resistance (Mai, Klinkenberg et al. 2010). 
Downregulation of PINK1 rendered cells more susceptible to the deleterious 
effect of ROS. Another PD-related protein, α-synuclein, has also been 
implicated in the promotion of mitochondrial fragmentation followed by the 
impairment of respiration and neurodegeneration (Nakamura, Nemani et al. 
2011). Further evidence supporting the role of disrupted mitochondrial 
dynamics in PD comes from a study showing that rotenone induces fission 
(Barsoum, Yuan et al. 2006). Another study demonstrated that nitrosative 
stress, as well as oxidative stress, can induce mitochondrial fragmentation 
(Nakamura, Lipton 2011).  
The key regulator of mitochondrial biogenesis, PGC1α, has been 
implicated in ageing and neurodegenerative diseases, such as Huntington’s 
Disease (HD; (Johri, Starkov et al. 2011) and PD (Zheng, Liao et al. 2010). It 
seems to be particularly important in PD as a meta-analysis of genomic studies 
revealed decreased expression of various genes controlled by     PGC1α in PD. 
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Genes affected include factors relating to the ETC and glucose metabolism. 
Shin and co-workers (2011) have shown that a protein called PARIS is 
regulated by Parkin. In the absence of functional Parkin, (a state noted in some 
PD cases), PARIS suppresses the expression of PGC1α, which confirms the 
importance of this transcriptional co-activator in the disease. It has been shown 
that PGC1α expression can be induced by ROS, and treatment with MPTP in 
PGC1α-null mice induces oxidative stress susceptibility as well as degeneration 
of dopaminergic neurons (St-Pierre, Drori et al. 2006).   
 
 
Figure 1.15. Role of PGC1α in mitochondrial biogenesis and antioxidant defence. Taken 
from (Finkel 2006)  
 
 
68 | P a g e  
 
 
PGC1α activation can also be regulated by Sirt1, which is NAD+/NADH 
dependent, and can be inhibited by factors such as increased NADH levels due 
to toxicant-induced complex I damage. However, one study investigating 
PGC1α mRNA levels in post-mortem sporadic PD brains revealed no 
differences compared to controls (Arthur, Morton et al. 2009). Nevertheless, the 
post-transcriptional regulation of PGC1α in PD has yet to be investigated. 
Mitochondrial biogenesis induced by PGC1α is controlled by the 
calcium/calmodulin-activated protein kinase family (CaMK), which also 
functions in neural synaptic stimulation (Wu, Kanatous et al. 2002). Interestingly, 
lead has been shown to activate calmodulin (Kern, Wisniewski et al. 2000), 
thus, there is a possibility that this heavy metal can indirectly affect the activity 
of PGC1α, which might in turn affect mitochondrial biogenesis. Moreover, 
prolonged lead-induced activation of calmodulin may lead to neuronal cell death 
via modulation of the activity of various CaMKs, such as calmodulin-dependent 
protein kinase II (Wright, Schellenberger et al. 1997).  
A number of signalling processes involving the mitochondria, the nucleus 
or inter-organelle communication, have been implicated in mediating the effects 
of ROS. Interestingly, PGC1α has been shown to be induced by endoplasmic 
reticulum (ER) stress, which has also been implicated in PD as described below 
(Wu, Ruas et al. 2011). It has been shown to directly interact with activating 
transcription factor 6 (ATF6), co-activate it, leading to the expression of a range 
of unfolded protein response (UPR) proteins, which help the cell to recover from 
the ER stress.   
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1.2.7 Mitochondria - ER crosstalk contribution to Parkinson’s Disease  
Upon oxidative stress, mitochondria and the endoplasmic reticulum 
critically contribute to apoptosis induction.  Fis1, apart from being involved in 
mitochondrial fission, plays a role in mitochondria – ER communication. It is the 
direct interaction of this protein with Bap31, an ER membrane localized protein 
playing an important role in cell death that provides a platform for caspase-8 
activation. This allows bi-directional communication between the two organelles 
and requires ER calcium release to support cell death (Alirol, James et al. 2006, 
Iwasawa, Mahul‐Mellier et al. 2011). As both the ER and mitochondria have 
been implicated in PD, investigating the Fis1-Bap31 interaction upon treatment 
with lead could provide information on the possible role of the crosstalk between 
these two organelles in lead-induced neurodegeneration. 
As mentioned above, one of the characteristic features of PD is 
formation of α-syn-containing Lewy bodies in neurons (Wakabayashi, Tanji et 
al. 2007).This is believed to be one of many stimuli present in PD that could 
trigger endoplasmic reticulum (ER) stress and lead to activation of the unfolded 
protein response (UPR;(Wu, Kim et al. 2008). The UPR is a homeostatic 
mechanism normally triggered by the accumulation of unfolded proteins in the 
ER. This process mediates a decreased in protein synthesis and an increased 
in protein folding or, if necessary, protein degradation. Increased activation of 
ER stress pathways, such as those mediated by IRE1 and PERK, has been 
found in post-mortem tissues from PD patients (Hoozemans, Van Haastert et 
al. 2007, Matus, Lisbona et al. 2008). Rotenone and MPP+ (active metabolite 
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of MPTP) have also been found to induce the UPR pathway (Ryu, Harding et 
al. 2002). Lead, which is the subject of the present investigation, has also been 
implicated in ER stress generation in the nervous system (Qian, Tiffany-
Castiglioni 2003). It has been shown that lead treatment causes upregulation 
of glucose regulated protein levels (GRP78), which is an ER stress marker, in 
a rat glioma cell line (Qian, Falahatpisheh et al. 2001). However, the 
mechanism that mediates this response is uncertain. Depletion of ER calcium 
is one of the factors that may cause increased GRP78 expression (Li, 
Alexandre et al. 1993). Pb2+ has previously been identified by Mas-Oliva (1989) 
as an ER Ca2+ -ATPase inhibitor, suggesting that lead-induced disruption of 
calcium homeostasis could lead to ER stress. Nevertheless, it cannot be 
excluded that lead directly interacts with proteins or chaperones, preventing 
protein folding and causing their accumulation in the unfolded state. Indeed, 
GRP78 itself has been shown to be one of the targets for Pb2+ binding (Qian, 
Harris et al. 2000). 
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Figure 1.16. Mitochondrial dysfunction in Parkinson’s disease.  
Various aspects of mitochondrial biology, depicted in the figure above, have been shown to 
play a role in pathogenesis of PD. The following cellular phenomena were experimentally 
shown in PD models: a) Complex I dysfunction; b) increased generation of ROS; c) mtDNA 
damage caused by ROS; d) bioenergetic failure due to decreased ATP production; e) release 
of pro-apoptotic factors from mitochondria leading to initiation of programmed cell death; f) 
defective mitophagy; g) mitochondrial calcium overload. Genes implicated in some familial 
forms of the disease were also shown to be involved in regulation of mitochondrial biology. CL, 
cardiolipin; Cyt. c, cytochrome c; HTRA2, high temperature requirement A2; IMM, inner 
mitochondrial membrane; IMS, intermembrane space; LRRK2, leucine-rich-repeat kinase 2; 
OMM, outer mitochondrial membrane PINK1, phosphatase and tensin homolog-induced kinase 
1; ROS, reactive oxygen species; TRAP1, tumor necrosis factor receptor-associated protein 1; 
α-syn, alpha-synuclein.  
Figure taken from http://www.vilalab.org/en/research/mitochondrial.php 
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Hypothesis 
Exposure to lead acetate has a negative effect on the function of dopaminergic 
neurons which might be mediated by increased generation of reactive oxygen 
species and / or disruption of cellular calcium balance.   
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Aims 
- Identify tolerated and toxic concentrations of lead acetate in 
dopaminergic cellular model 
- Determine the impact of lead exposure on mitochondrial function 
- Assess the involvement of reactive oxygen species in lead-induced 
neurotoxicity 
- Determine the possible role played by lead-induced disruption of 
cellular calcium balance 
- Identify the key players / molecular mechanism involved in cellular 
response to lead insult 
- Use an in vivo model to validate any conclusions reached using the 
in vitro system 
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Materials and methods 
2.1 Declaration of responsibilities  
All live animal procedures as well as immunohistochemistry experiments were 
performed by Prof. Jose Luis Venero from University of Seville, Spain.  
XF Cell Mito Stress Test (Sehorse Biosciences) was performed in collaboration 
with Aine Henley from Francis Fraser Labs, Hammersmith Campus. 
All other data were produced, collected and analysed by myself. 
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2.2 Reagents 
Sigma-Aldrich 
 2-mercaptoethanol (M7522), acrylamide (40% solution, A7168), agarose 
(A9539), ammonium persulfate (A3678), ampicillin sodium salt (A9518), 
BAPTA/AM (A1076), bovine serum albumin (BSA, A7906), calcium chloride 
(C7902), dimethyl sulfoxide (D2650), DMEM (D5671), doxorubicin (D1515), 
EGTA (E4378), foetal calf serum (F7524), glucose (G7021), HEPES (H3375), 
LB-broth (L3022), Lead (II) acetate trihydrate (215902), L-glutamine (G7513), 
NP-40 (I3021), PBS tablets (P4417), penicillin/streptomycin (100 U/ml and 10 
mg/ml; P4333), Polybrene® (H9268), propidium iodide solution (1mg/ml, 
P4864), puromycin dihydrochloride (P8833), sodium azide (S8032), sodium 
butyrate (30,341-0), sodium pyruvate (S8636), TEMED (T9281), Triton X-100 
(T8532), TWEEN® (P5927), 10x sterile PBS (D1408); all of the 
oligonucleotides used. 
Thermo fisher 
10x PBS (14200-067), DiOC6 (D273), Fluo-4/AM (F14217), MAX Efficiency® 
Stbl2™ Competent Cells (10268-019), Mito Tracker® Red CMXRos (M7512), 
Opti-MEM (22600134), 15070-063), Pierce Agarose ChIP Kit (26156), Platinum 
SYBR-Green QPCR Supermix-UDG (111733-046), pLenti7.3/V5-TOPO® TA 
cloning kit (K5310-00), PureLinkTM HiPure plasmid filter purification kit (K2100-
07), Thermoscript RT-PCR system (11146-024), TMRE (T669) and Trypsin-
EDTA solution (0.5%, 15400-54),  
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Fermentas  
5x protein loading buffer (R0891), 6x DNA loading dye (R0611), 50x TAE buffer 
(#B49), Bradford reagent (500-0006), GeneRulerTM 1kb DNA ladder 
(SM0314), GeneRulerTM 1kb plus DNA ladder (SM1334), PageRulerTM 
prestained protein ladder (SM0671), ProteoBlockTM protease inhibitor cocktail 
(R1321). The following restriction enzymes were also purchased from 
Fermentas: AgeI (FD1464), BamHI (FD0055), EcoRI (FD0274), HindIII 
(FD0505), NcoI (FD0575), SacI (FD1134), XhoI (FD0695) and T4 DNA ligase 
HC (EL0013).  
EMD Biosciences 
Thapsigargin (586005)  
Bio-Rad Laboratories 
0.5M Tris-HCl pH 6.8 solution (161-0799), 1.5M Tris-HCl pH 8.8 solution (161-
0798), 10x TGS buffer (161-0772) and SDS solution (10% w/v, 161-0416) 
GE Healthcare 
HyperfilmTM high performance chemoluminescent film (28906837) 
Millipore 
CaspaTagTM caspase-3/7 in situ assay kit (APT423), CaspaTagTM caspase-
8 in situ assay kit (APT408) 
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Qiagen 
Effectene (301427); RNeasy Mini Kit (74104); QIAshredder (79656) 
Biotium 
GelRedTM nucleic acid gel stain (41002) 
Addgene 
pLKO.1 – TRC cloning vector (Plasmid 10878) 
GFP-PGC1α (Plasmid 4) 
 
2.3 Commonly Used Buffers 
Luria-Bertani (LB) Broth 
1% Bacto tryptone, 0.5% Bacto-yeast extract, 1% NaCl. pH 7.5 (NaOH) 
Phosphate Buffered Saline (PBS) 
137mM NaCl, 2.7mM KCl, 8mM NA2HPO4 and 2mM KH2PO4. pH 7.4 
RIPA buffer 
150 mM NaCl, 1% NP-40, 0.5% w/v sodium deoxycholate, 0.1% w/v SDS, 
7450 mM Tris-HCl. pH 8.0 
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SOC medium 
2% tryptone, 0.5% yeast extract, 10 mM NaCl, 10 mM MgSO4, 2.5 mM KCl 
and 20 mM glucose 
TAE buffer 
40 mM Tris-acetate and 1 mM EDTA at pH 8.3 
TBS 
50 mM Tris-HCl (pH 7.4), 155 mM NaCl 
TE buffer 
100 mM Tris-HCl (pH 7.5) and 10 mM EDTA (pH 8.0) 
TGS buffer 
25mM Tris, 192mM Glycine and 0.1% w/v SDS 
Sodium-dodecyl sulfate (Stacking gel) 
4.8% polyacrylamide, 125 mM Tris-HCl pH 6.8, 0.1% SDS, 0.1% APS and 0.1% 
TEMED  
Sodium-dodecyl sulfate (Resolving gel) 
10-15% polyacrylamide, 375 mM Tris-HCl pH 8.8, 0.1% SDS, 0.1% APS 
and 0.05% TEMED 
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2.4 Cell culture and treatments 
 
Rat mesencephalon-derived cell line (1RB3AN27; hereafter referred to as 
N27 cells) was used as an in vitro model for studies of dopaminergic 
neurodegeneration. N27 cells comprise a homogenous population of tyrosine 
hydroxylase expressing cells with functional characteristics resembling 
dopaminergic neurons.  N27 cells were maintained in RPMI-1640 medium 
(Sigma) supplemented with 10% FBS (Sigma), 100 U/ml penicillin and 100 
µg/ml streptomycin (Sigma) at 37°C in a 5% CO2 humidified atmosphere. All 
experiments were conducted in cells passage 2–20. Cells were exposed to lead 
(II) acetate (Sigma) dissolved in distilled water added to the growth medium at 
5, 100 and 500 µM for 48 h (unless stated otherwise). Upon treatment 
termination cells were harvested using 0.25% trypsin (Sigma). Cell density was 
measured using a Neubauer chamber.  
HEK293FT cells were used for viral production. These cells were grown 
in Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma) supplemented with 
10% FBS (Sigma), 2 mM L-glutamine (Sigma), 100 U/ml penicillin and 100 
µg/ml streptomycin (Sigma) at 37°C in a 5% CO2 humidified atmosphere. Cells 
were harvested using 1% trypsin (Sigma).  
Cell lines with proteins stably down-regulated by Lentiviral shRNA 
transfection were cultured as described above in the presence of 1 μg/ml 
puromycin (Sigma). 
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2.5 Assessment of mitochondrial function 
2.5.1 Mitochondrial superoxide measurement 
 
Mitochondrial superoxide levels were measured using MitoSOX™ Red 
(Invitrogen). 5 mM MitoSOX stock solution was prepared by dissolving the 
contents of one vial in 13 µl of DMSO. Cells used for the experiment, grown in 
a 6 well plate, were treated with indicated concentrations of lead acetate and 
incubated for 48 h at 37°C in 5% CO2. Upon treatment termination cells were 
harvested as described before and washed with PBS. 5 µM MitoSOX solution 
was prepared in PBS and 0.5 ml was used to resuspend harvested cells. Cells 
were incubated with the reagent for 15 min and washed three times with PBS 
once the incubation was complete. After final wash step, PBS was removed 
and 150 µl of fresh PBS was used to resuspend the cells for FACS analysis. 
FACSCalibur™ (BD Biosciences) was used for data collection and Cyflogic 
software (CyfLo Ltd.) for the analysis. 
 
2.5.2 Mitochondrial membrane depolarisation 
Cells were harvested as described above and resuspended in 150 µl of 
PBS containing 40 nM 3,3-dihexaoxacarbocyanine iodide (DiOC6(3)) and PI (50 
μM) for 40 min at 37°C. Cells were then analysed using FACSCalibur™. (FL-1 
channel was used for DiOC6(3) staining and FL-3 for PI). Cyflogic (CyfLo Ltd.) 
was used for the analysis of obtained data. 
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2.5.3 Mitochondrial respiration assessment  
The Seahorse XF analyser was used according to manufacturer’s 
guidelines (Seahorse Bioscience). Cells were seeded at 40000 cells/well in a 
Seahorse Bioscience V7 tissue culture plate. Reagents used for mitostress test 
included Oligomycin (1 µg), Carbonyl cyanide-4-(trifluoromethoxy) 
phenylhydrazone (FCCP, 0.2 µg), Antimycin/Rotenone (0.25 µg). OCR values 
were measured by XF24 extracellular flux analyser. Data was normalised to the 
total protein amount in each well quantified using a standard BSA / Bradford 
method described below.  
 
 
Figure 2.1 Use of different mitotoxic compounds to investigate different aspects of 
mitochondrial function. 
Taken from http://www.seahorsebio.com/products/consumables/kits/cell-mito-stress.php 
accessed on 10/11/14 
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2.6 Caspase activity measurement 
 
Caspase activity assays were performed using CaspaTag™ caspase-
3/7 or 8 assay kit (Millipore) according to the manufacturer's protocol followed 
by data collection with FACSCalibur™ (BD Biosciences) and analysis with 
Cyflogic (CyfLo Ltd.). Briefly, stock solutions of the FLICA reagents were 
prepared by dilution of the contents of each vial in 50 µl of DMSO (making it a 
150x stock reagent). An aliquot of the stock solution was further diluted 5 times 
in PBS (pH 7.4) to prepare a 30x working stock. Cells were harvested as 
described above (1500 rpm for 5 min) and washed with PBS. Following that, 
cells were resuspended in 300 µl of PBS and 10 µl of FLICA reagent was added. 
Samples were incubated for 1 hour at 37°C in 5% CO2. Subsequently, 1 ml of 
1x Wash buffer (prepared according to manufacturer’s instructions) was added 
to the tubes which were then spun at 350 g for 5 min at RT. Supernatant was 
removed and cells were washed twice with 1x Wash buffer. After last 
centrifugation step, pellets were resuspended in 200 µl and analysed 
immediately at FL-1 channel using FACSCalibur™ (BD Biosciences).  
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2.7 Clonogenic assay 
 
Two hundred N27 cells were seeded into each well of a 6-well plate. 
Cells were allowed to grow overnight and were subsequently treated with lead 
acetate for 48 h. Upon treatment termination medium was removed and cells 
were washed with PBS. PBS was discarded and cells were fixed with cold 100% 
methanol for 10 min at -20°C. Another PBS wash was performed and cells were 
stained with Giemsa solution (5% Giemsa, 25% methanol in PBS) for 10 min at 
RT. Next, wells were washed with distilled water and plates were allowed to 
dry. Colonies were counted using ImageJ software using scanned images of 
the plates.  
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2.8  Investigation of gene expression 
 
2.8.1 RNA extraction from cells 
Total RNA extraction was performed using QiaShredder columns and 
the RNeasy extraction kit (Qiagen).  
Briefly, ca. 1 x 106 cells were harvested following lead acetate treatment. 
350 µl of RLT was used to resuspend and lyse the cells. Lysates were 
transferred to QIAShredder columns and spun for 2 min at full speed (13000 
rpm). 350 µl of 70% ethanol was added to each sample and mixed thoroughly. 
Samples were transferred to RNeasy spin columns and centrifuged for 15 s at 
13000 rpm. 700 µl of RW1 buffer was used to wash each column which was 
subsequently spun for 15 s at 13000 rpm and the flow-through was removed.   
Membranes were washed twice with 500 µl of RPE buffer for 15 s 
followed by 2 min at 13000 rpm. To harvest the RNA, columns were placed in 
new collection tubes, loaded with 40 µl of RNase-free water and spun at 13000 
rpm for 1 minute. RNA concentrations and quality were confirmed using 
NanoDrop 1000 (Thermo Scientific). 
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2.8.2 RNA extraction from tissue 
500 µl ice-cold Trizol reagent was added to the samples which were 
subsequently homogenized. 100 µl choloroform was added, samples were 
gently mixed and spun at 12000 rpm at 40C for 15 min. The aqueous phase 
was collected. 1 µl glycogen (20ug/ul; Invitrogen) was added. 250µl isopropanol 
was added and samples were spun at 12000 rpm at 40C for 10 min. 
Supernatant was removed. Pellet was air-dried. 400 µl 75% ethanol was added 
and pellet was resuspended. Samples were spun at 7000 rpm at 40C for 5 min. 
Ethanol was removed and pellet air-dried and subsequently dissolved in 15-20 
µl RNAse free water. RNA concentrations and quality were confirmed using 
NanoDrop 1000 (Thermo Scientific). 
 
2.8.3 Real-time PCR 
5 µg of RNA was used to synthesize cDNA using the ThermoScript™ 
RT-PCR first strand synthesis system (random hexamer primer method) 
according to manufacturer’s instructions (Invitrogen).  
Platinum SYBR Green qPCR SuperMix-UDG (Invitrogen) was used for 
qPCR analysis. Primers were designed using Primer Blast (see table 1). Real 
time PCR reactions were performed using a Stratagene Mx3000P instrument. 
MxPro Software (Stratagene) was used to obtain Ct values. Transcript levels 
relative to GAPDH were determined using the standard curve method. 
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Target Primer sequence 
MFN1 F CCATCACTGCGATCTTCGGCCA 
MFN1 R CAGCGAGCTTGTTTCTGTAGCCCT 
MFN2 F CTCTGTGCTGGTTGACGAGT 
MFN2 R AGCGGTCAGACATGTTTCGT 
FIS1 F GTAGGGTTACATGGATGCCCAGAGA 
FIS1 R GGCAACAGCTCCTCCAGCAG 
DRP1 F GGTGGAATTGGAGATGGTGGTCGA 
DRP1 R TTCGTGCAACTGGAACTGGCACA 
PGC1α F ACTGAGCTACCCTTGGGATG  
PGC1α R TAAGGATTTCGGTGGTGACA 
TFAM F GTCGCGTGGGACAAACCGGA 
TFAM R CACATCTCGACCCCCGTGCG 
GAPDH F GGGGCTCTCTGCTCCTCCCTG 
GAPDH R CGGCCAAATCCGTTCACACCG 
CaNB F TCCAACCGAGACTCCGCCCG 
CaNB R GACGGCGGCTTTGCTGTCCG 
NRF1 F  TTACT TGCTGTGGCTGATGG 
NRF1 R  CCTCTGATGCTTGCGTCGTCT 
NRF2 F  CAGAGCAAGTGACGAGATGG 
NRF2 R CCGAAATGTTGAGTGTGGTG 
  
Table 1. The list of primers used for Q-RT-PCR analysis 
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2.9 Immunocytochemistry 
 
2.9.1 Mitochondrial staining 
MitoTracker® Orange CMTMRos staining was used to investigate the 
structure of mitochondrial filaments.  
MitoTracker stock was dissolved in DMSO to a final concentration of 
1mM. Working solution was prepared in a standard RPMI 1640 medium 
supplemented with FCS and antibiotics due to the fact that an oxidised form of 
MitoTracker was used. The working concentration used in the experiment was 
250 nM. Cells treated with indicated concentrations of lead were grown on 
coverslips in a 6 well plate. Upon treatment termination, medium was aspirated 
and replaced with a pre-warmed staining solution. Cells were subsequently 
incubated with MitoTracker for 45 min at 37°C, 5% CO2. Once the incubation 
was finished, cells were subject to the standard immunostaining protocol 
described below.  
 
2.9.2 Immunostaining 
Following treatment, growth medium was removed and cells were 
washed with PBS. Subsequently, cells were incubated with 4% 
paraformaldehyde (v/v in PBS) for 10 min at 4°C. The paraformaldehyde was 
removed and coverslips were washed with PBS three times for 10 min with 
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gentle rocking. Next, cells were incubated for 1 hour at room temperature with 
blocking / permeabilization buffer (10 mM HEPES, 0.3% Triton X-100, 3% BSA, 
pH 7.4). Following blocking, coverslips were incubated overnight with Pgc1α 
antibody (4 °C, overnight; Everest) at a concentration recommended by a 
manufacturer, diluted in blocking / permeabilization buffer; 50 µl were used for 
each ø 10 mm coverslip. After incubation with the primary antibody, cells were 
washed three times for 10 min with PBS. Following overnight incubation, cells 
were stained with AlexaFluor 488 anti-goat IgG secondary antibody (RT, 1 h; 
Molecular Probes). Subsequently, coverslips were washed 3 times with PBS. 
Nuclei were counterstained with Hoechst (1 µg ml−1, Molecular Probes) and 
mounted using Vectashield mounting medium (VWR). Cells were analysed 
under a Leica TCS SP5 scanning confocal microscope. Images were analysed 
using Leica LAS AF Lite software.  
 
2.9.3 Mitochondrial Surface Quantification 
ImageJ software with a Mito-morphology macro tool was used to quantify the 
surface of mitochondria in each sample. 30 cells were selected for analysis for 
each sample. The mean mitochondrial surface area value was calculated and 
plotted.  
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2.10 Sodium Dodecyl Sulfate-Polyacrylamide (SDS) Gel 
Electrophoresis 
 
2.10.1  Protein extraction  
Following treatment, cells were harvested and subject to protein 
extraction. Cells were lysed on ice for 30 min using TGN lysis buffer (1 M Tris-
HCl, 2.5 M NaCl, Glycerol, 0.5 M glycerophosphate, Tween 20 and Nonidet 
P40; completed with EDTA-free protease inhibitor (Roche)). During lysis, cells 
were vortexed every 10 min. Cell lysate was cleared by centrifugation at 
maximal speed for 10 min at 4 °C. Supernatant was collected for protein 
concentration analysis using Bradford assay. 
 
2.10.2 Protein quantification 
200 µl of Bradford reagent (BioRad; diltuted in water) were added to 
each well of a 96-well plate. BSA (Sigma) was dissolved in water and added to 
the wells containing Bradford reagent at a series of known concentrations (0-
10 µg/µl) to produce a standard curve. Whole cell lysate samples were diluted 
(1:5) and 1 µl of each sample was added per well (procedure performed in 
triplicate). The 96-well plate was placed on a shaker for 1 min followed by 
absorbance measurement (at 595 nm) using FLUOstar Optima (BMG Labtech). 
Values recorded for BSA dilutions were used to produce a standard curve that 
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was subsequently used to quantify the amount of proteins in the experimental 
samples.  
2.10.3 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis  
50-120 µg of proteins were run on a 10% SDS-PAGE gel (stacking gel: 
4.8% polyacrylamide, 125 mM Tris-HCl pH 6.8, 0.1% SDS, 0.1% APS, 0.1% 
TEMED; resolving gel: 10-polyacrylamide, 375 mM Tris-HCl pH 8.8, 0.1% SDS, 
0.1% APS, 0.05% TEMED) in TGS-running buffer (25 mM Tris-HCl, 192 mM 
Glycine, 0.1% w/v SDS; BioRad). PageRuler prestained protein ladder (Thermo 
Scientific) was used as protein size marker. Samples were subject to gel 
electrophoresis for 15 min at 90 V followed by ca. 60 min at 120 V. 
Subsequently, protein transfer to nitrocellulose membranes (GE healthcare) 
was performed at 400 mA for 90 min in transfer buffer (TGS buffer with 20% 
methanol).  
2.10.4 Immunoblotting  
Membranes were blocked with 5% non-fat dry milk dissolved in PBS with 
0.01% Tween 20 (Sigma) and subsequently washed three times in PBS. 
Incubation with primary antibodies was performed overnight at 4°C (see table 
2 for the antibody list).  Following two PBS washed, membranes were incubated 
with isotype-matched secondary antibody conjugated with horseradish 
peroxidise, diluted in milk, for 1 h at RT. Peroxidase activity was developed 
using ECL and detected with chemoluminescence film (GE Healthcare). 
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2.11 Chromatin Immunoprecipitation.  
2.11.1  Fixing and cross-linking 
Cross-linking and fixing of cells were performed as described previously 
(Nelson, Denisenko et al. 2006). Briefly, N27 cells were treated with lead 
acetate and subsequently fixed with formaldehyde by addition of 80 µl of 37% 
(w/v) formaldehyde to 2 ml of overlaying medium (final concentration of 1.42%) 
followed by a 15 min incubation at RT. After fixation 282 µl of 1 M glycine were 
added to the medium (125 mM final concentration) and cells were incubated for 
5 min at RT. Cells were subsequently collected by scraping, spun down at 2000 
g for 5 min at 4°C and pellets were washed twice with cold PBS.  
 
2.11.2  Lysis and digestion with MNase  
The following steps of the ChIP protocol were performed following the 
instructions provided by the manufacturer of the Agarose ChIP kit (Thermo 
Scientific). Briefly, 100 µl of lysis buffer 1 was added to each pellet which was 
then vortexed for 15 s followed by 10 min incubation on ice. Next, samples were 
spun down at 9000 g for 3 min; supernatant was discarded. Nuclei were 
resuspended in 100 µl of MNase Digestion Buffer. 0.25 µl of Micrococcal 
Nuclease (10 U/µl) was added to each sample which was subsequently 
vortexed and incubated and left on ice for 5 min. Next, samples were spun down 
at 9000 g for 5 min, supernatant was removed, nuclei were resuspended in 50 
µl of Lysis Buffer 2 containing protease/phosphatase inhibitors and samples 
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were incubated on ice for 15 min with 15 s vortexing every 5 min. Subsequently, 
chromatin was centrifuged at 9000 g for 5 min and the supernatant was 
transferred to new tubes.  
 
2.11.3  Immunoprecipitation 
10% of each sample was transferred to a new tube and kept as total 
input. The remaining 45 µl of supernatant was added to 455 µl of 1x IP Dilution 
Buffer. Diluted lysate was added to plugged spin columns and supplemented 
with 5 µg of PGC1α antibody. Samples were left on a rotor for an overnight 
incubation at 4°C. On the following day 20 µl of ChIP Grade Protein A/G Plus 
Agarose resin was added to each sample which was then incubated on a rotor 
for 1 h at 4°C. Next, plugs were removed, columns were placed in new 
collection tubes and spun at 3000 g for 30 s. Flow-through was discarded, plugs 
were placed back on the columns which were then loaded with 0.5 ml of IP 
Wash Buffer 1 and incubated for 5 min on a rocking platform at 4°C. 
Subsequently, samples were centrifuged at 3000 g for 30 s, flow-through was 
removed and the washing process was repeated twice with IP Wash Buffer 2 
and once with IP Wash Buffer 3. Once the flow-through was removed after the 
final wash, samples were spun down again for 1 min to remove any residual 
wash buffer.  
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2.11.4  IP Elution 
After re-fitting column plugs, 1x IP Elution Buffer was added to the 
samples which were then incubated at 65°C for 30 min on a rotor. In the 
meantime, 1.5 ml Eppendorf tubes were prepared for each sample, containing 
6 µl of 5 M NaCl and 2 µl of Proteinase K. 10% input samples were defrosted 
and mixed with 150 µl of IP Elution Buffer and 6 µl of 5 M NaCl and 2 µl of 
Proteinase K. Once the incubation of IP samples was finished, columns were 
placed in the previously prepared Eppendorfs and centrifuged at 6000 g for 1 
min. Columns were subsequently discarded, IP and total input samples were 
vortexed and placed in a 65°C heat-block for 1.5 h.  
 
2.11.5  DNA recovery  
750 µl of DNA Binding Buffer was added to each sample, 500 µl of which 
was subsequently transferred to a DNA Clean-Up column placed in a 2 ml 
collection tube. Columns were spun at 10000 g for 1 min and the flow-through 
was discarded. The process was repeated with the remaining 250 µl of each 
sample. 750 µl of DNA Column Wash buffer was used to wash the samples. 
Following removal of the flow-through, samples were spun again at 10000 g for 
2 min to remove any residual wash buffer. Columns were then placed in new 
1.5 ml Eppendorf tubes and 50 µl of DNA Column Elution Solution was added 
to the centre of each membrane. Samples were centrifuged at 10000 g for 1 
min and the DNA-containing flow-through was collected. DNA concentration 
was checked using a Nanodrop 1000.  
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Samples were used for Q-RT-PCR analysis. Ct values were normalised 
according to the following equation:  
∆Ct [normalised ChIP] = (Ct [ChIP] – (Ct [input] – log2 (0.1))).  
The % input was calculated with the following equation:  
% input = 2(-∆Ct[normalised ChIP]).  
For the list of target promoter primer pairs see the table below.  
 
Target Primer sequence 
Promoter DRP1 F CAGATTCACGGACCCAGCTT 
Promoter DRP1 R CAAAGGCTGTCGGGAGATGT 
Promoter PGC1a F GGACCTTTGCTGTTTGCCTG 
Promoter PGC1a R GCCACCAACTCTAAACCGGA 
Promoter SOD2 F CCTGGCCTTCTAATCCCGAC 
Promoter SOD2 R CCCTGAGGTTAGGGTTGCTG 
 
Table 2. Target promoter primers used for ChIP analysis. 
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2.12 Production of stably transfected cell lines  
2.12.1 Cloning of shRNA  
For the sequence of shRNA primers see Table 3. One μl of each primer 
(from 3 mg/ml stock) was added to 48 μl of the annealing buffer (100mM NaCl, 
50mM HEPES pH7.4). After vortexing, samples were incubated at 90°C for 4 
min, 70°C for 10 min then slowly brought down to 37°C over a period of ca. 1 
h. 2 μg of pLKO.puro TRC cloning vector (AddGene) was digested with AgeI 
and EcoRI Fast Digest restriction enzymes (Fermentas) for 20 min at 37°C.  
Following digestion, DNA was separated using a 1% agarose (Sigma-Aldrich) 
gel and the vector backbone (7026 bp) was purified according to the protocol 
described below. T4 DNA ligase (Fermentas) was used to ligate the purified 
vector backbone with previously designed primers. Prior to bacterial 
transformation (see below), AgeI endonuclease was used to remove self-
ligated vector backbone.  
 
2.12.2 Viral particles production 
The pLKO.1-TRC cloning vector was obtained from AddGene. 
Oligonucleotides containing shRNA were designed and cloned into the vector 
according to the manufacturer’s protocol. For shRNA primers used see Table 
3.  
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Virions were produced in HEK293T cells, grown in 10 cm dishes, by 
combining three packaging plasmids (pVSV-G (5.4 μg), pRev (3.8 μg), 
pGag.Pol (7.8 μg)) obtained from Invitrogen with pAdVantage (9 μg, Promega), 
and pLKO vector (20 μg). 437.5 μl of water and 62.5 μl of 2 M CaCl2 was added. 
After 5 min, complexes were mixed with 2×HBS (500 μl) and added to cells 
dropwise. After an overnight incubation fresh DMEM medium containing 1 mM 
sodium butyrate (Sigma) was added. To harvest the viruses, 48 h post-
transfection, the supernatant was collected, spun down and filter-sterilized 
(0.45 μm filter). N27 cells were transduced for 8 h in the presence of polybrene 
(6 μg/ml; Sigma). Cells were selected with puromycin (5 μg/ml) 3 days after 
transduction and cultured for further 4 days. On completion of selection, cells 
were maintained in 1 μg/ml puromycin containing medium. 
 
Target Primer sequence 
Scramble shRNA F CCGGCCTAAGGTTAAGTCGCCCTCGCTCTAGCGAGGGCGACTTAACCTTAGGTTTTTG 
Scramble shRNA R AATTCAAAAACCTAAGGTTAAGTCGCCCTCGCTCTAGCGAGGGCGACTTAACCTTAGG 
shRNA BAP31 F CCGGGACGCCTGGTGACTCTCATTTCTCGAGAAATGAGAGTCACCAGGCGTCTTTTTG 
shRNA BAP31 R AATTCAAAAAGACGCCTGGTGACTCTCATTTCTCGAGAAATGAGAGTCACCAGGCGTC 
 
 
Table 3. shRNA primers used to create cell lines with stable knockdown of genes of 
interest. 
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2.13 DNA electrophoresis and gel extraction 
The digests (mixed with 6x DNA loading dye from Fermentas) were 
separated on a 1% agarose (Sigma-Aldrich) gel (1% w/v of agarose dissolved 
in TAE buffer with GelRed nucleic acid stain added at 1/20000 dilution) to 
confirm the presence of the insert. GeneRuler 1kb plus DNA ladder 
(Fermentas) was used as a size marker. Two DNA fragments of 2 and 5 kbp 
are expected if the shRNA was correctly inserted whereas 2 and 7 kbp 
fragments are expected if the shRNA was not cloned.  
After vector backbone bands were cut out of the agarose gel they were 
placed in 1.5 ml Eppendorf tubes and extracted using a QIAquick Gel Extraction 
Kit from Qiagen according to the protocol provided. Briefly, three volumes of 
QG buffer were added to 1 volume of gel. Following 10 min incubation at 50°C, 
once gel slices were completely dissolved, 1 gel volume of isopropanol was 
added. The sample was loaded into the QIAquick column and centrifuged for 1 
min. Flow-through was removed, samples were washed with 0.5 ml of QG 
buffer and, subsequently, with 0.75 ml of PE buffer. Flow-through was 
discarded and samples were spun for an additional minute at 13000 rpm. To 
elute DNA, columns were placed in new Eppendorfs and 30 μl of buffer EB (10 
mM Tris-HCl, pH 8.5) was added, samples were left at RT for 1 min and 
subsequently spun for 1 min at 13000 rpm.  
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2.14 Bacterial transformation 
MAX Efficiency® Stbl2™ Competent Cells (Invitrogen) were used for 
transformation. The process was performed according to manufacturer’s 
protocol. Briefly, cells were thawed on ice and 50 μl was used for 
transformation. Ligated primers were diluted 1:5 in Tris-HCl (pH 7.5) and 1 mM 
EDTA and 1 μl was added to the competent cells. Cells were gently mixed and 
incubated on ice for 30 min. Next, cells were subject to a heat-shock at 42°C 
for 45 s and placed back on ice for 2 min. 0.45 ml of room-temperature S.O.C. 
Medium was added to the cells which were subsequently incubated at 37°C 
with gentle shaking (225 rpm) for 2 h. Cells were spread on LB plates with 100 
μg/mL ampicillin and allowed to form colonies overnight at 37°C. Colonies were 
picked for plasmid isolation which was performed according to the protocol 
described below. 
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2.15 DNA Plasmid isolation  
The PureLink® HiPure Plasmid Filter Miniprep and Maxiprep Kits were 
used for plasmid extraction. Plasmids were purified following manufacturer’s 
protocol. Briefly, overnight cultures (5 ml for Miniprep and 200 ml for Maxiprep) 
were spun down at 4000 g for 10 ml. Supernatant was removed and pellets 
resuspended in 10 ml Resuspension Buffer (with added RNase A). 10 ml of 
Lysis Buffer was added, samples were mixed and incubated at RT for 5 min. 
Following that, 10 ml Precipitation Buffer was added and samples were mixed 
by inverting the tube and subsequently spun down at 12000 g for 10 min at RT. 
Binding of the DNA was performed by loading the supernatant onto the column 
(equilibrated by adding 30 ml of Equilibration Buffer followed by draining by 
gravity flow) and allowing it to pass through the filter by gravity flow. 15 ml of 
Elution buffer was applied to the column and the flow-through containing the 
DNA was collected in a sterile tube. 10.5 ml of isopropanol was added to the 
eluate and the contents were mixed. Samples were spun down at 12000 g for 
30 min at 4°C. Supernatant was discarded. Pellet was resuspended in 2 ml of 
70% ethanol and samples were centrifuged at 13000 g for 5 min at 4°C. After 
removal of the supernatant pellets were air-dried for 10 min. DNA was 
resuspended in 500 µl of TE buffer. Final concentrations of plasmids were 
checked using a NanoDrop 1000 spectrophotometer (Thermo Scientific). 
Plasmids were stored at -20°C 
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2.16 Transfections 
GFP-PGC1α plasmid transfections were performed using Xfect 
transfection reagent (Clontech) following manufacturer’s protocol. 
Briefly, cells were seeded in 10 cm Petri dishes and allowed to grow 
overnight before transfections were performed. Medium was changed the 
following day prior to transfection.  
For each dish 30 µl of DNA (pEGFP-C1 or GFP-PGC1α plasmid) was 
mixed with 570 µl of Xfect Reaction Buffer. Xfect polymer was vortexed and 9 
µl was added to the diluted plasmid DNA. Tubes were vortexed for 10 s at high 
setting and subsequently incubated for 10 min at RT. After allowing 
nanoparticles to form, complexes were added dropwise to the Petri dishes. 
Cells were incubated overnight with the nanoparticle complexes. Ca. 70% of 
cells were successfully transfected. On the following day medium was changed 
and cells were treated with indicated concentrations of lead acetate.   
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2.17 Quantification of cellular calcium 
Cytosolic and ER calcium measurement 
Cells grown in a 6-well plate were exposed to lead acetate for 24 h.  
Following the treatment, cells were resuspended in PBS containing 2 μM Fluo-
4/AM (Thermo fisher) and subject to a 45 min incubation at 37°C in a 5% CO2 
incubator with frequent agitation. Cells were subsequently washed twice with 
PBS and resuspended in 150 µl of PBS.  FACS analysis was performed using 
FACSCalibur (BD Biosciences). FL-1 channel was used during the acquisition 
at a linear scale. In order to investigate the ER calcium levels, following ca. 60 
s measurement of baseline, cytosolic calcium, 10 µM thapsigargin was used to 
release the cation from the ER. Kinetic analysis of the obtained data was 
performed using FlowJo software (Tree Star Inc.) and the difference between 
the baseline fluorescence and the maximum fluorescence observed after 
thapsigargin addition was interpreted as calcium released from ER.  
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2.18  Animals, treatment and experimental procedures 
 
Twenty male albino Wistar rats (250-270 g) were kept at constant room 
temperature of 22 ± 1 ºC and relative humidity (60%) with a 12-h light-dark cycle 
(8:00 a.m.-8:00 p.m.), with free access to food and water containing either lead 
acetate (500 ppm) or sodium acetate (equivalent in acetate concentration to the 
one received by lead acetate group) for 14 weeks. Then, half of the animals 
were killed by decapitation (RT-PCR experiments) or by perfusion 
(immunohistochemistry experiments). Rat substantia nigra were dissected with 
reference to a standard rat brain atlas (Paxinos and Wilson, 6th Edition, 
Elsevier), immediately snap-frozen in liquid nitrogen and stored at -80°C. Total 
RNA was extracted using the method described above (see 2.7.2) 
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2.19  Immunohistochemistry 
Thaw-mounted 20-μm coronal sections of brain were cut on a cryostat 
at –15 ºC and mounted in gelatin-coated slides. For double-labelling of DRP1 
with NeuN, sections were blocked with PBS containing 1% normal goat serum 
and horse serum (Vector) for 1 h. The slides were washed three times in PBS 
and then incubated overnight at 4ºC with rabbit-derived anti-DRP1 (1:300; Cell 
Signalling) and mouse-derived anti-NeuN (1:1000; Millipore) diluted in PBS 
containing 1% normal goat/horse serum and 0.25% Triton X-100. Sections 
were incubated with goat anti-rabbit secondary antibody conjugated to 
fluorescein (1:200, for DRP1; Vector) and horse anti-mouse secondary 
antibody conjugated to Texas Red (1: 200, for NeuN; Invitrogen) for 1 h. Nuclei 
were counterstained with Hoechst (1 µg ml−1, Molecular Probes). Fluorescence 
images were acquired using a confocal laser scanning microscope (Zeiss LSM 
7 DUO) and processed using the associated software package (ZEN 2010). 
Signal intensity was quantified using an Image Analysis Program from Soft 
Imaging System (analySIS®, Germany) 
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2.20  Quantification of tyrosine hydroxylase positive neurons 
Tissue sections were incubated with an anti-TH primary antibody 
(1:5000 in PBS-T with 3% normal rabbit serum at 4 °C), followed by incubation 
with biotinylated secondary antibody (diluted 1:200, biotinylated antibody, 
Vector Laboratories) overnight at 4 °C. Next, an avidin–biotin peroxidase 
enzyme complex was used following manufacturer’s protocol (Vectastain Elite 
ABC kit). TH immunoreactivity was visualized using 0.05% DAB, as well as 
0.04% hydrogen peroxide in PBS. Sections were mounted in Vectashield 
(Vector Laboratories). 
The number of TH-positive neurons in the SN was estimated using a 
fractionator sampling design (Gundersen et al. 1988). Counts were made at 
regular predetermined intervals (x = 150 μm and y = 200 μm) within each 
section. An unbiased counting frame of known area (40 × 25 μm = 1000 μm2) 
was superimposed on the tissue section image under a 100× oil immersion 
objective. Therefore, the area sampling fraction is 1000/(150 × 200) = 0.033. 
The entire z-dimension of each section was sampled; hence, the section 
thickness sampling fraction was 1. In all animals, 20-μm sections, each 100 μm 
apart, were analyzed; thus, the fraction of sections sampled was 20/100 = 0.20. 
The number of neurons in the analyzed region was estimated by multiplying the 
number of neurons counted within the sample regions by the reciprocals of the 
area sampling fraction and the fraction of section sampled. 
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2.21 Statistical analysis 
Unpaired two-tailed student’s t-test was used as a statistical analysis 
tool. Samples were regarded having an equal variance if the f-test between two 
data sets was p>0.05. Results were regarded as statistically significant if 
p<0.05. 
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Results 
Mitochondrial dysfunction has long been known to play an important role 
in various neurodegenerative conditions. Abnormalities in different aspects of 
mitochondrial biology, such as biogenesis, dynamics or changes in the 
structure of the organelle, have been implicated in different disease states.  
Neuronal cells have a particularly high energetic demand which makes them 
exceptionally sensitive to changes in mitochondrial function. The neurotoxin, 
lead has been previously described as mitotoxic but the exact mechanism of its 
action in neurons remains unclear.  
N27 cells, derived from rat mesencephalon, were used to evaluate the 
effect of lead on mitochondria in neurons. N27 cells are from E12 rat 
mesencephalon, transfected with SV40 T-antigen genes to achieve 
immortalisation (Prasad, Carvalho et al. 1994). The cells express tyrosine 
hydroxylase as well as dopamine transporter and have been accepted as a 
suitable model for studies of neurodegeneration and neurotoxicity in both, a 
differentiated and undifferentiated form (Clarkson, Edwards-Prasad et al. 
1999).  
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3.1 Dose-response assessment 
Since no data have been published on the effect of lead treatment on 
N27 cells, a preliminary investigation had to be performed in order to identify 
appropriate concentrations of lead for future experiments. A range of 
concentrations of lead was selected based on previously published 
experiments using other neuronal cells. Cells were treated with a range of lead 
(II) acetate concentrations for a period of 48 h. The effect of the treatment on 
mitochondria and on cell death was evaluated using DiOC6(3) and PI co-
staining followed by FACS analysis. Positively charged DiOC6(3) accumulates 
inside mitochondria in proportion to mitochondrial membrane potential Δψm. 
More polarized mitochondria (with more negative matrix charge) accumulate 
more positively charged dye, and depolarized mitochondria (matrix is less 
negative) uptake less dye.  
FACS analysis revealed that lead causes depolarisation of the 
mitochondrial membrane (Fig. 3-1A) as well as subsequent cell death (Fig. 3-
1B). Interestingly, there was no clear pattern of dose-dependent response of 
mitochondria observed at the chosen concentrations. Doxorubicin, known to 
induce mitochondrial potential loss and cell death, was used as a positive 
control. MitoSOX staining used to investigate mitochondrial superoxide 
production (as an indicator of mitochondrial ROS levels) showed a slight 
increase in mitochondrial superoxide generation upon treatment but the results 
were not statistically significant (Fig. 3-1C). 
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Figure 3.1. Effects of exposure of dopaminergic cells to lead. N27 cells were treated with 
indicated lead concentrations for 48 h. (A) The effect of lead treatment on mitochondrial 
membrane potential dissipation was detected by DiOC6(3) staining followed by FACS analysis. 
(B) Analysis of cell death was performed using PI staining. (C) Mitochondrial ROS were 
measured using MitoSOX staining followed by FACS analysis. *P<0.05, **P<0.01, ***P<0.001, 
n=3. Bars represent means + SE. 
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3.2 Lead induces mitochondrial dysfunction and subsequent 
apoptosis of dopaminergic neurons. 
 
Based on the range finding studies on the effects of lead on  N27 cells 
reported above, concentrations of 5 µM, 100 µM and 500 µM were selected for 
use in further experiments. The last concentration was selected to determine 
whether lead at a concentration even higher that those used previously would 
have a more deleterious effect. 
At the highest lead concentration, lead had a much more pronounced 
impact on dopaminergic neurons than at the concentrations used previously. 
FACS analysis of cells stained with MitoSOX revealed an almost 100% 
increase of mitochondrial superoxide at this concentration, whereas at 5 µM 
and 100 µM the increase was only approx. 25% (Fig. 3-2 A). A similar response 
trend was observed for mitochondrial membrane depolarisation (Fig. 3-2 B) as 
well as for cell death (Fig. 3-2 C), with 500 µM having a much more deleterious 
impact on the cells. 500 µM (high) was therefore classified as toxic, whilst 5 µM 
(low) and 100 µM (moderate) concentrations of lead were classified as 
tolerated, i.e. not inducing excessive cell death. It should be noted that despite 
a 20-fold difference, both of the tolerated concentrations had a very similar 
effect on the cells seen across three independently conducted experiments.  
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Figure 3.2. Lead induces mitochondrial dysfunction and subsequent death of 
dopaminergic neurons. (A) Mitochondrial superoxide levels were measured using MitoSOX 
staining followed by FACS analysis. (B) The effect of lead treatment on mitochondrial 
membrane potential loss was detected by DiOC6(3). (C) Analysis of cell death measured by 
propidium iodide (IP). *P<0.05, **P<0.01, ***P<0.001, n=3. Bars represent means + SE. 
 
 
Western blot analysis of PARP cleavage (Fig. 3-3), which is a hallmark 
of apoptosis, demonstrated that the type cell death induced by lead, as 
observed by PI staining of the cells was apoptosis and, again, was much more 
pronounced in cells treated with the toxic concentration of lead (500 µM). 
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Having established that lead targets mitochondria of dopaminergic 
neurons, Seahorse XF24 mitochondrial stress analysis was performed to 
further investigate mitochondrial function.  
While a reduction in basal respiration was observed in cells treated with 
= 500 µM lead (Fig. 3-4 A), there was quite a lot of variability in this parameter, 
and the decrease was not statistically significant. A general trend was observed 
for a dose-dependent decrease in ATP production (Fig. 3-4 B) with the highest 
lead concentration (500 µM) causing a significant (P<0.01) reduction, of more 
than 50%.Maximal respiration decreased in a dose-dependent manner (Fig. 3-
4 C). Proton leak was reduced at the toxic concentration of lead, but again there 
was appreciable variability in this measurement, and the change was not 
statistically significantly (Fig. 3-4 D). Interestingly, mitochondrial reserve 
capacity levels were markedly reduced with all concentrations of lead (P<0.01) 
including 5 µM, a concentration which did not have any significant effect on the 
other measures of mitochondrial function investigated with the seahorse XF24 
(Fig. 3-4 E). Non-mitochondrial respiration was not statistically significantly 
Figure 3.3. Lead induces PARP cleavage in N27 cells.  
Western blot analysis was used to investigate PARP cleavage 
following lead exposure. β-actin was used as a loading control. 
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affected at tolerated concentrations but was significantly reduced at the toxic 
concentration (Fig. 3-4 F).  
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Figure 3.4. Oxygen consumption is decreased in cells exposed to lead for 48 h. Basal 
respiration was measured using a Seahorse XF24 Analyzer (A), along with oxygen used for 
ATP production (respiratory control ratio; basal OCR minus OCR after oligomycin injection; B), 
maximum respiratory capacity (OCR after injection of 2.5 μM FCCP; C), proton leak (OCR 
difference between OCR post oligomycin injection and non-mitochondrial respiration OCR 
value; D), spare respiratory capacity (OCR post injection of 2.5 μM FCCP minus basal OCR; E), 
and non-mitochondrial respiration (OCR after injection of antimycin A and rotenone; F). Data 
was normalised to the total protein amount in each well. Data are expressed as means ± SE; 
*P<0.05, **P<0.01, ***P<0.001; n=4.  
 
 
 
3.3 PGC1α protects dopaminergic neurons from Pb2+-induced 
neurotoxicity 
 
Disruption of mitochondrial biogenesis and dynamics has previously 
been implicated in various neurodegenerative conditions including Parkinson’s 
disease. One of the key regulators of mitochondrial metabolism is PGC1α, a 
transcriptional co-activator which plays a vital, upstream role in a network 
governing mitochondrial biogenesis and is known to respond to, and regulate, 
cellular ROS levels.  
 In order to determine whether PGC1α plays a role in the response 
of N27 cells to lead, its expression at the transcriptional as well as protein level 
was evaluated (Fig. 3-5 A, B). Both PGC1α mRNA and protein expression were 
increased following exposure of DA neurons to µM lead, but surprisingly only 
at a concentration of 100 µM. The functional significance of this, if any, was 
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investigated by determining whether the expression of the PGC1α target gene, 
Nrf1, a transcription factor activating expression of nuclear genes involved in 
respiration as well as mitochondrial DNA transcription and replication (Fig. 3-5 
C), was also affected. Nrf1 mRNA levels were significantly increased only at 
100 µM lead. The expression of Tfam, a mitochondrial transcription factor that 
is one of NRF1’s targets, showed a similar pattern to that of Nrf1.  
  
 
Figure 3.5. Exposure of N27 cells to 100 μM lead for 48 h induces expression of PGC1α 
and its target genes. (A,B) qRT-PCR and western blotting measurement of mRNA and protein 
expression levels of Pgc1α in N27 cells treated with lead for 48h. (C) mRNA levels of Pgc1α 
targets genes (Tfam, Nrf1). Bars represent means ± SE; *P<0.05, **P<0.01, ***P<0.001, n=3.  
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Since there was no difference in the degree of mitochondrial toxicity 
induced by 5 and 100 µM lead, despite a 20-fold difference in concentration, 
but induction of PGC1α expression was observed at the higher concentration 
of lead, it was concluded that the transcription co-activator may play a protective 
role in DA cells, preventing excessive damage to mitochondria. Since the toxic 
concentration (500 µM) of lead did not seem to affect Pgc1α mRNA levels, its 
expression after 3 h of exposure was evaluated in order to see whether such a 
high, toxic concentration of lead simply triggers a different transcriptional 
response or whether at an earlier time point the same mechanism is triggered 
initially (here, 3 h post exposure) but, having failed to potentially protect against 
the insult, is switched off by the cell in favour of a more relevant response aimed 
at dealing with a highly toxic insult (Fig. 3-6). 
 
 
 
  
 
Figure 3.6. Pgc1α expression is induced 3 hours 
after lead treatment.  
Q-RT-PCR was used to investigate Pgc1α mRNA 
levels in N27 cells treated with lead for 3 hours. Bars 
represent means ± SE; *P<0.05, **P<0.01, 
***P<0.001, n=3.  
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Whilst exposure of N27 cells to 100 µM lead for 3-hour caused a modest 
increase in Pgc1α expression, exposure to 500 µM resulted in over 10-fold 
increase in its mRNA level at this time. This observation led to the conclusion 
that the transcription of Pgc1α is induced by a tolerated dose of lead (100 µM), 
which is maintained over time and can still be observed after exposure for 48 
hours, whereas with a toxic concentration of lead (500 µM) although there is a 
marked, early induction of Pgc1α, after exposure for 48 h this has returned to 
control levels.  
 Based on these data, it was hypothesised that PGC1α might play 
a protective role against lead insult at intermediate concentrations (100 µM). In 
order to investigate this, PGC1α was stably knocked-down using a lentiviral 
shRNA vector. Successful knockdown was achieved, as shown by the 
decrease in Pgc1α mRNA level and reduced clonogenicity (Fig. 3-7 A). To 
determine whether downregulation of PGC1α expression has any impact on 
lead-induced mitochondrial ROS generation and loss of mitochondrial 
membrane potential, MitoSOX (Fig. 1-7 B) and DiOC6(3) (Fig. 3-7 C) staining 
were used, followed by FACS analysis. shPGC1α cells proved to be much more 
susceptible to lead insult. While both, ROS generation and mitochondrial 
membrane depolarisation were increased in the knockdown cells treated with 
lead compared to the Pb-treated control, even the untreated cells with 
downregulation of PGC1α produced more mitochondrial superoxide compared 
with their wild-type untreated counterpart.  
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Figure 3.7. Protective role of PGC1α against lead toxicity. (A) Pgc1α mRNA levels in N27 
cells with stable downregulation of PGC1α by lentiviral shRNA (shPGC1α) and in the negative 
control cells (scramble) and corresponding  CGA images depicting reduced ability to form large 
colonies in shPGC1α cells. (B) Mitochondrial superoxide levels were measured in shPGC1α 
cells using MitoSOX staining. (C) The effect of 48 h lead treatment on mitochondrial membrane 
potential loss in shPGC1α cells was detected by DiOC6(3).  Bars represent means means ± 
SE; *P<0.05, **P<0.01, n=3.  
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3.4 Role of Pb2+ and PGC1α in control of mitochondrial 
dynamics in vitro. 
  
Since PGC1α controls mitochondrial biogenesis (a process of formation 
of new mitochondria within the cell) and has been suggested to play a role in 
regulation of mitochondrial dynamics (mitochondrial movement and changes in 
connectivity mediated by fission and fusion processes), confocal microscopy 
was employed to investigate the filament structure of mitochondria expressing 
mitoRFP in cells treated with lead (Fig. 3-8).  
 Interestingly, elongation of mitochondrial filaments was observed 
in N27 cells treated with 100 µM lead, but not with 500 µM. Compared with 
untreated cells, mitochondria in cells exposed to the tolerated dose displayed 
pro-fusion characteristics. The toxic dose of lead resulted in general shrinkage 
of cytoplasm (a hallmark of apoptosis), reduction of the mitochondrial network 
and visible fragmentation of these organelles.  
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Figure 3.8. Lead causes changes in the structure of mitochondrial filaments in 
dopaminergic neurons. (A) Confocal imaging analysis of N27 cells stained with MitoTracker 
Orange. Nuclei stained with DAPI. (B) Mitochondrial surface area was quantified using ImageJ 
software with Mito-Morphology macro tool. Bars represent means ± SE; *P<0.05, **P<0.01, 
n=3.  
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Due to the fact that 100 µM Pb caused increased expression of PGC1α 
as well as elongation of mitochondrial filaments, PGC1α was overexpressed to 
determine its effect on mitochondrial morphology, directly. The expectation was 
that increased PGC1α expression would promote mitochondrial fusion and 
protect the cells against lead toxicity.  
 
 
Figure 3.9. An ambiguous role of PGC1α. (A) Pgc1α mRNA levels in lead-treated cells, 
transfected with a PGC1α-encoding vector. (B) Immunocytochemistry and confocal imaging 
analysis of co-transfection of N27 cells with PGC1α-encoding vector and mitoRFP. Nuclei were 
stained with DAPI. Bars represent means ± SE; *P<0.05, ***P<0.001, n=3.  
 
 
Q-RT-PCR analysis of PGC1α mRNA levels (Fig. 3-9 A) revealed that 
while overexpression of the transcription co-activator successfully increased its 
transcript levels, treatment of the transfected cells with lead for 48 h caused a 
further, dose-dependent upregulation of its expression. The toxic concentration 
led to over a 45-fold increase of PGC1α transcript levels.  
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Surprisingly, and contrary to expectations, overexpression of PGC1α did 
not cause elongation of mitochondrial filaments (Fig. 3-9 B). Indeed, 
upregulation of PGC1α expression increased the susceptibility of the cells to 
lead-induced toxicity. Cells treated with both the lower (100 µM) and the higher 
(500 µM) concentration of lead appeared unhealthy, with condensed cytoplasm 
and nuclei, hallmarks of apoptotic cell death. It has to be noted that in WT cells 
treated with 100 µM lead, PGC1α mRNA levels doubled relative to control. In 
N27 cells overexpressing PGC1α, treated with this concentration of lead, there 
was an over 4-fold increase in the transcript level.  
 Since overexpression of PGC1α did not help shed light on its role 
in the control of mitochondrial dynamics, Q-RT-PCR was used to investigate 
the expression of genes which code for proteins involved in this process. 
Mitochondrial fission is known to be driven by DRP1 and FIS1 while the proteins 
involved in fusion are OPA1, MFN1 and MFN2. Q-RT-PCR analysis of the 
expression of genes coding for MFN1, MFN2, DRP1 and FIS1 was performed 
(Fig. 3-10 A).  
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Figure 3.10. Lead and PGC1α-induced changes in the expression of mitochondrial 
fission and fusion genes. (A) qRT-PCR analysis of the expression of mitochondrial fusion 
(Mfn2) and fission (Drp1, Fis1) genes upon 100 µM lead treatment. (B) qRT-PCR analysis of 
the expression of Drp1 and Mfn1 in PGC1α overexpressing cells. Bars represent means ± SE; 
*P<0.05, n=3.  
 
Exposure of cells to 100 µM lead for 48-hours induced expression of the 
mitochondrial fusion protein, Mfn2, whilst at the same time reducing 
transcription of Drp1, a mitochondrial fission protein. Fis1 was not affected by 
the treatment. Thus, Pb2+ leads to a shift towards a pro-fusion expression profile 
of mitochondrial genes regulating the dynamics of this organelle. 
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Since it had been shown that exposure to lead had an effect on fission 
and fusion proteins and on PGC1α, the relationship between these effects was 
investigated, particularly as there was evidence that PGC1α co-activates 
transcription of Mfn2. Hence, it was hypothesised that the effects of lead 
exposure on the pro-fusion mitochondrial profile could be mediated by its effect 
on PGC1α. N27 cells overexpressing PGC1α were subject to Q-RT-PCR 
analysis (Fig. 3-10 B). It was found that increased expression of this 
transcription co-activator stimulates the transcription of Mfn1 and causes a 
slight, statistically insignificant, drop of Drp1 mRNA levels. It appears that 
PGC1α may have a direct role in control of mitochondrial dynamics via 
regulation of mitofusins and, possibly, Drp1.  
To further test this hypothesis, chromatin immunoprecipitation was 
performed. PGC1α antibody was used to pull down chromatin sheared with 
micrococcal nuclease and Q-RT-PCR was performed using primers designed 
to target the promoter regions of genes of interest (Fig. 3-11). 
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Figure 3.11. PGC1α associates with the promoters of Drp1, Nrf1 and SOD2. ChIP assay 
was performed to determine the binding of PGC1α to the promoters of Nrf1, SOD2 (positive 
controls, known to be regulated by PGC1α) and Drp1. Bars represent means ± SE; *P<0.05, 
n=3.  
 
The PGC1α promoter region was selected as a positive control due to 
the fact that this transcription co-activator has been shown to regulate its own 
expression via an auto-regulatory loop. Nrf1 and Sod2 were chosen as other 
targets known to depend on PGC1α for transcription initiation. Enrichment of 
chromatin fractions containing all three genes of interest was observed upon 
treatment of cells with lead. Since, it had already been shown that the Mfn2 
promoter associates with PGC1α, the association of this co-activator with the 
Drp1 promoter was evaluated. Interestingly, it was found that PGC1α does bind 
to the promoter of the mitochondrial fission protein which is very surprising 
given that previous experiments suggested a decrease of Drp1 transcription in 
response to a rise of PGC1α levels (which was statistically significant in cells 
treated with lead, expressing increased levels of the transcription co-activator). 
Since PGC1α is a co-activator of transcription, reduced occupancy of the Drp1 
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promoter was expected which would account for a drop in its expression. 
However, it has to be remembered that there are other proteins, such as 
transcription factors, that are required for initiation of transcription and co-
activators are just a part of a complex transcription machinery.  
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3.5 Lead-induced changes in the expression of genes 
controlling mitochondrial biogenesis and dynamics in vivo. 
 
Having established the relationship between lead and changes in 
mitochondrial function and structure in vitro, an in vivo investigation was 
performed to determine if the same effects occur in brain tissue of animals 
exposed to the heavy metal. Adult rats were given lead acetate in their drinking 
water for a period of 14 weeks. Water provided to control rats contained sodium 
acetate. After animals were terminated, brain tissues were harvested. 
Comparison of number of TH-positive neurons (as an indication of 
dopaminergic neurons) was performed to check whether exposure to lead 
acetate for 14 weeks had an effect on their viability. Such exposure did not lead 
to a reduction in the number of DA neurons (Fig. 3-12 C). Q-RT-PCR analysis 
was performed on substantia nigra as this dopaminergic neuron-containing 
region of the midbrain is the primary target of Parkinson’s disease. Striatum 
tissue was also analysed to determine if the effects of lead vary between 
different brain regions. The nigrostriatal pathway, involved in the control of 
movement, relies on communication between the SNpc and the striatum.  
 The Q-RT-PCR analysis confirmed the majority of the findings 
with the in vitro cellular model system. Pgc1α expression was increased in the 
substantia nigra of animals exposed to lead (Fig. 3-12 A). As a functional 
consequence of this induction of PGC1α expression, transcript levels of its 
target genes, Nrf1, Nrf2 and Tfam were also increased. While mRNA levels of 
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both mitofusins were elevated (similar to the effect seen in N27 cells), Drp1 
expression was also increased in response to lead, in contrast to the 
observation in vitro. The transcription profile of mitochondrial genes of the 
striatum showed an expression pattern similar to that for the SN (Fig. 3-12 B). 
The only exceptions were Nrf1 and Mfn2, levels of which did not change 
significantly.  
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Figure 3.12 Lead induces changes in the expression of genes regulating mitochondrial 
biogenesis and dynamics in neurons in vivo. Transcript levels of PGC1α, its downstream 
targets and mitochondrial fusion and fission genes in substantia nigra (A) and striatum (B) of 
rats exposed to 500 ppm of lead-acetate versus control animals given water with acetate only 
for a period of 14 weeks. C) Substantia nigra tissue section images immunostained for TH, from 
control (left) and lead treated animals (right) showed no significant difference in the number of 
TH-positive neurons.  *P<0.05, **P<0.01, ***P<0.001, n=6. Bars represent means + SE. 
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To find an explanation for the surprising increase of Drp1 expression in 
brain tissue of lead-exposed animals, expression of this gene was investigated 
at an early time point in vitro (Fig. 3-13).  
 
 
 
Relative to control, following exposure to lead for 3 hours, Drp1 mRNA 
levels were increased in N27 cells (similar to findings in vivo). It is very difficult 
to identify the correct concentration of a chemical and time-point for use in in 
vitro experiments that reflect the status quo of dopaminergic neurons at a 
selected time post-exposure in vivo (14 weeks in the case of the present 
investigation). Thus, the possibility exists that the short term (3 h) exposure of 
N27 cells to lead in vitro corresponds to a 14-week exposure in animals. Also, 
it has to be remembered that there are limitations to in vitro cellular models and 
there might be factors involved in the in vivo response to lead that are not 
present in the in vitro model which could have an impact on the way the cells 
respond to the stressor.  
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The tissue from the substantia nigra used in this experiment was a 
heterogeneous mixture of different cell types, with dopaminergic neurons 
comprising only a very small percentage of the total. Since in vivo the increase 
in Drp1 was not consistent with the observations in vitro, confirmation was 
sought that this finding was true for neuronal cells per se, rather than reflecting 
a global increase in Drp1 throughout the whole tissue, representing Drp1 status 
in glial cells (comprising most of the substantia nigra), rather than neurons. To 
achieve this, SN sections were immunostained with DRP1 and NeuN (neuronal 
nuclei marker) antibodies and co-stained with Hoechst.  
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80 Figure 3.14. Elevation of DRP1 levels in SN neurons of rats 
exposed to lead. Confocal immunofluorescence microscopy of 
sections of substantia nigra of rats given 500 ppm lead acetate in 
drinking water for 14 weeks. Sections were incubated with primary 
antibodies targeting DRP1 and NeuN. Nuclei were stained with 
Hoechst (HST). Control animals (top panel) were given water 
containing acetate. Scale bar: 175 μm (A and B); 70 μm (C-H). DRP1 
levels were quantified using ImageJ software (I). An outline was 
drawn around each neuronal cell (NeuN positive) and mean 
fluorescence was measured (Select cell of interest  Analyse  
Measure). Measurement was repeated for 50 control and 50 lead-
treated cells. Acetate mean DRP1-positive cells = 34.38; lead mean 
DRP1-positive cells = 56.59. Bars represent means means ± SE; 
**P<0.01, n=3.  
I 
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Figure 3-14 clearly shows that in cells treated with lead, green fluorescence, 
indicative of DRP1 expression, is much more pronounced. It is also clear that 
this co-localizes with neuronal cells indicating that it is a specific effect of lead 
on this particular type of cell in the substantia nigra.  
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3.6 Reactive oxygen species and their downstream role in the 
cellular response to lead. 
PGC1α is co-induced with a battery of anti-oxidant enzymes in response 
to oxidative stress (Valle, Alvarez-Barrientos et al. 2005, St-Pierre, Drori et al. 
2006). Moreover, reactive oxygen species were identified as agents capable of 
triggering a change in mitochondrial filament structure, causing a ‘thread-grain 
transition’ via fission propagation (Pletjushkina, Lyamzaev et al. 2006). Thus, 
having observed an elevation of ROS levels as well as PGC1α induction and 
changes in mitochondrial morphology following exposure of N27 cells to lead, 
ROS appeared as a plausible upstream regulator of this cellular response.  
 
 
 
Figure 3.15. NAC does not prevent lead-induced mitochondrial membrane 
depolarisation. Pre-treatment of N27 cells with 1 mM NAC for 1 hour followed by a 48h lead-
exposure was used to investigate the impact of ROS on mitochondrial depolarisation. Bars 
represent means + SE. 
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Pre-treatment of N27 cells with 1 mM NAC, to inhibit ROS production, 
for 1 hour prior to 48 h exposure to lead did not prevent the loss of mitochondrial 
membrane potential. Therefore, ROS were excluded as a potential key player 
in lead-induced toxicity (Fig. 3-15).  
 
 
3.7 Calcium as the master regulator of lead-induced toxicity in 
dopaminergic cells. 
Since lead is known to mimic calcium in cellular milieu (Simons 1993), 
and ROS were excluded as the key regulators of the cellular response to Pb2+,  
the focus of the current investigation shifted towards calcium in the context of 
lead-induced disruption of dopaminergic cell function. It had previously been 
shown that lead affects calcium balance in a variety of different cells, including 
neuronal cells, but there is very little information available on whether such 
changes are involved in alterations of mitochondrial biogenesis and dynamics 
in DA neurons.  
Effects on cytoplasmic and ER calcium levels were investigated using 
Fluo-4/AM, an intracellular calcium indicator. ER calcium levels were 
determined using thapsigargin, a sarco/endoplasmic reticulum calcium ATPase 
(SERCA) inhibitor, which induces release of ER-stored calcium. The difference 
between the baseline fluorescence and the readings taken after thapsigargin 
administration was used to infer the levels of [Ca2+]ER. 
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Figure 3.16. Lead treatment causes a disruption of cellular calcium balance. N27 cells 
treated with lead acetate for 48 h were tested for cytoplasmic (A) and ER calcium levels (B) 
using thapsigargin, which was added after 45 seconds of measurement of baseline 
fluorescence (indicated by an arrow in the right panel) using Fluo-4/AM staining followed by 
flow cytometry analysis. Right panel shows representative scatter plots of untreated and lead-
treated samples with time (s) and fluorescence intensity represented on the X and Y axes 
respectively. Bars represent means ± SE; *P<0.05, n=3.  
 
 
Cytoplasmic calcium levels were elevated upon treatment with lead (Fig. 
3-16 A). The increase in [Ca2+]C was similar with all concentrations of lead used. 
Lead caused release of calcium from the ER calcium stores as shown in panel 
B of figure 4-15, which was more marked with the intermediate and high 
concentrations of the cation.  
To test whether these effects on Ca2+ play an upstream role in the 
cascade of cellular events triggered by lead exposure, the impact of preventing 
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and cell death was investigated. This was achieved by using BAPTA-AM, a 
calcium chelator, which has previously been shown and used to prevent 
fluctuations in intracellular calcium levels (Rintoul, Baimbridge 2003, Keating, 
Cork et al. 1994).  
 
 
 
Figure 3.17. Pre-treatment of N27 cells with BAPTA-AM prevents lead-induced 
mitochondrial membrane potential loss and cell death. Pre-treatment of N27 cells with 5µM 
BAPTA-AM for 1 hour followed by a 48h lead-exposure was used to investigate the impact of 
calcium on mitochondrial depolarisation (A) and cell death (B) following lead treatment. Bars 
represent means + SE; *P<0.05, n=3.  
 
FACS analysis revealed that prevention of intracellular calcium 
imbalance in cells treated with 100 μM lead prevents mitochondrial 
depolarisation (Fig 3-17 A) and subsequent cell death (Fig 3-17 B). It appears 
that calcium has an extremely important, upstream role in the cellular response 
to lead insult.  
 Since it has been suggested that BAP31 residing in the ER 
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triggering calcium release and mitochondrial fission (Breckenridge, Stojanovic 
et al. 2003), BAP31 expression profile was investigated after treatment of cells 
with lead.  
 
 
  
There is very little known about BAP31 expression changes in response 
to external or internal stimuli and what could be the physiological significance 
of fluctuations of levels of this protein. However, it has been shown that there 
is an association between overexpression of BAP31 and less aggressive 
behaviour of colorectal cancer that could potentially be attributed to the role that 
this ER-localised protein plays in apoptosis induction via release of ER calcium 
which is subsequently taken up by mitochondria (Dong, Jiang et al. 2011). 
Western blot analysis revealed elevation of BAP31 in cells treated with 100 and 
500 μM lead (Fig. 3-18), consistent with the idea that its raised expression 
contributes to cell death induction via alteration of mitochondrial homeostasis. 
To further explore the possibility that BAP31 is one of the important players in 
the cellular response to lead, a BAP31 stable knockdown N27 cell line was 
generated. This was the preferred method of downregulation as it avoids 
potential artefacts generated through transient transfections.  
BAP31
28
42ß -actin
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Fig. 3.18. BAP31 expression is induced by lead 
treatment.  
N27 cells treated for 48 h with indicated 
concentrations of lead were lysed and the total 
protein was extracted. Lysate was subjected to 
SDS-PAGE and Western blotting of  BAP31. β-
actin was used as a loading control.   
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Figure 3.19. Stable downregulation of BAP31 renders N27 cells less susceptible to lead 
toxicity. BAP31 downregulation was achieved using a lentiviral shRNA vector (pLKO.puro) 
with shRNA sequence targeting the transcript of interest (shBAP31). Scramble shRNA (SC) 
was used as a negative control. (A) Total protein lysates from shBap31 and SC cells were 
subjected to western blot analysis to confirm successful downregulation of BAP31. shBap31 
and SC cells treated with 100 μM lead for 48 h (blue bars) were analysed with FACS to test for 
mitochondrial superoxide generation (MitoSOX; B), mitochondrial depolarisation (DiOC3(6); C), 
caspase 3/7 activation (CaspaTag 3/7; D) and caspase 8 activation (CaspaTag 8; E). (F) FACS 
scan image examples. Bars represent means + SE; *P<0.05, n=4.  
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As depicted in panel A of figure 3-19, BAP31 was successfully stably 
decreased in N27 cells (ca. 74% reduction as quantified using ImageJ). 
Downregulation of BAP31 expression led to an attenuation of the induction of 
ROS generated by mitochondria on exposure to lead (Fig. 3-19 B).    What is 
more, knockdown of BAP31 completely prevented mitochondrial depolarisation 
induced by lead (Fig. 3-19 C). There was also mitigation of activation of the 
major executioner caspases 3 and 7 (Fig 3-19 D) as well as complete 
abrogation of the increase in initiator caspase 8 activity (Fig. 3-19 E). This is 
consistent with previous findings showing an involvement of calcium in the 
regulation of the activation of different caspases i.e. elevated calcium triggering 
caspase activation (Amoroso, D'Alessio et al. 2002, Jo, Jun et al. 2004, Tantral, 
Malathi et al. 2004).  
 To determine whether the observed protection is lead specific, not 
just a phenomenon that is ubiquitously observed upon exposure to any toxicant 
/ harmful agent, shBap31 cells were exposed to lipopolysaccharide for 48 h and 
their response to the treatment was examined (Fig. 3-20). 
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Figure 3.20. Stable downregulation of BAP31 does not affect cellular response to LPS. 
BAP31 downregulation was achieved using a lentiviral shRNA vector (pLKO.puro) with shRNA 
sequence targeting the transcript of interest (shBAP31). Scramble shRNA (SC) was used as a 
negative control. (A) Total protein lysates from shBap31 and SC cells were subjected to western 
blot analysis to confirm successful downregulation of BAP31. shBap31 and SC cells treated 
with 1 μg/ml LPS for 48 h (blue bars) were analysed with FACS to test for mitochondrial 
superoxide generation (MitoSOX; B), mitochondrial depolarisation (DiOC3(6); C), caspase 3/7 
activation (CaspaTag 3/7; D) and caspase 8 activation (CaspaTag 8; E). Bars represent means 
+ SE; *P<0.05, n=4.  
 
Figure 3-20 clearly shows that downregulation of BAP31 had no 
significant impact on the response of N27 cells to LPS. None of the aspects of 
cellular machinery investigated were affected by the knockdown relative to SC 
cells. 
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Calcium, which regulates the activity of a number of different proteins, 
such as calmodulin and calcineurin, has been shown to indirectly play a part in 
regulation of PGC1α expression via modulation of the activity of those proteins 
(Chin, Olson et al. 1998, Schaeffer, Wende et al. 2004). 
Having established that calcium is crucial in mediating the response of 
dopaminergic cells to lead, expression of calcineurin (which induces PGC1α 
expression), was scrutinised upon exposure of dopaminergic cells to lead.  
 
 
Fig. 3-21 The effect of lead on calcineurin expression. RNA extracted from N27 cells treated 
for 48 h with lead was subjected to Q-RT-PCR analysis using calcineurin primers. Bars 
represent means + SE; *P<0.05, n=3.  
 
 
Interestingly, the observed pattern of calcineurin expression was very 
similar to that obtained for PGC1α. While 5 μM did not lead to any change in 
calcineurin expression, a distinctively high calcineurin mRNA level was 
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observed at 100 μM (over a 2-fold increase). 500 μM induced a slight, but 
significant, elevation of the transcript levels but this was much lower than at with 
the medium concentration of lead. Interestingly, lead has previously been show 
to have an ambivalent impact on the expression of calcineurin, depending on 
its concentration (Kern, Audesirk 2000). 
 
 
3.8 Lead does not cause activation of microglia. 
 Microglia, a type of glial cell, are the resident macrophages of the 
central nervous system in vertebrates. Upon exposure to certain stimuli 
signalling CNS insult, microglia undergo a change from a resting to a reactive 
state. Activated microglia are known to be involved in a variety of neurological 
pathologies, including Parkinson’s disease (Barcia, Bahillo et al. 2004, Croisier, 
Moran et al. 2005).  
 While the present investigation focused on dopaminergic 
neurons, the primary group of cells directly affected in Parkinson’s disease, a 
possible involvement of microglia had to be evaluated to establish the full 
picture of a possible mechanism by which lead exerts its deleterious effect. 
Moreover, lead had previously been shown to cause microglial activation when 
administered at very high doses (Sobin, Montoya et al. 2013). In order to 
answer the question about microglial engagement in the process, BV2 murine 
microglia were used. These cells are widely accepted as a suitable model for 
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study of inflammatory responses and are considered as a reliable alternative to 
primary microglia (Henn, Lund et al. 2009, Stansley, Post et al. 2012). Since 
these cells were previously shown to have phagocytic properties, an in vitro co-
culture system was established, using CellTracker™ Green CMFDA dye, to 
look for possible morphological changes in BV2 cells cultured with 
dopaminergic cells, exposed to lead. Moreover, enzyme-linked immunosorbent 
assay (ELISA), was used to test BV2 cells for interleukin production, a 
phenomenon which is a hallmark of their activation.  
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Figure 3.22. Lead treatment does not cause activation of microglia. (A) Microscopy 
imaging of co-cultured dopaminergic neurons (DA) stained with CellTracker and microglia (MG) 
treated with 100 µM lead or positive controls (paraquat 100µM and LPS 1µg/ml). No change in 
microglial morphology (reflecting their activation) was observed upon lead treatment. (B) Lead 
treatment does not induce secretion of proinflammatory cytokines by microglia as indicated by 
ELISA. LPS was used as a positive control. Bars represent means + SE; n=3 
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BV2 cells (Fig. 3-22 A) and led to morphological changes characteristic for their 
activation such as formation of filopodia (Sheng, Zong et al. 2011). However, 
exposure to lead did not induce any visible morphological changes in the cells. 
The notion that Pb2+ does not lead to BV2 cell activation was supported by the 
absence of any detectable change in the levels of pro-inflammatory cytokines 
after exposure of cells to lead (Fig. 3-22 B). LPS, on the other hand, led to a 
potent elevation of IL-6 and TNFα in the culture medium of BV2 cells incubated 
with the endotoxin for 48 hours.  
 Taken together, these data provide evidence that lead has a 
direct effect on dopaminergic neurons rather than an indirect effect mediated 
by triggering of an inflammatory response via microglial activation.  
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Discussion 
4.1 Summary of the study 
 
In this study, I propose a mechanism explaining the neurotoxic effect that 
lead has on dopaminergic neurons. I demonstrate for the first time that 
exposure of dopaminergic neurons to lead induces changes in both 
mitochondrial biogenesis and dynamics and that these effects are mediated by 
changes in PGC1α.  
I show that Pb2+ has differential effects on neuronal cells, depending on 
the concentration of the toxicant to which cells are exposed (Fig. 3.1 and 3.2). 
At lower, tolerated concentrations it induces an adaptive response which 
enables the cell to withstand the insult while at higher concentrations, lead has 
a more acute effect leading to excessive cell death (Fig. 3.3).  
More detailed study revealed that mitochondria play a key role in the neuronal 
response to lead and dictate the fate of the cell (Fig. 3.4). I have shown that at 
a high tolerated concentration (100 µM), there is induction of PGC1α expression 
(Fig. 3.5), which acts to promote development of an extensive mitochondrial 
network, thus working to prevent oxidative damage to the cell and maintain 
cellular ability to generate energy under stress conditions. Exposure of DA 
neurons to the tolerated concentration of Pb2+ was accompanied by a shift in 
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the expression of mitochondrial dynamics genes towards a higher ratio of fusion 
to fission mRNAs (3.10). This transcriptional change, also shown in vivo in rats 
administered lead in their drinking water, was reflected in an elongation of 
mitochondrial filaments (3.12). However, I observed a discrepancy in the 
changes in the expression of Drp1, a mitochondrial fission gene, in vitro and in 
vivo, which will be discussed below. While knockdown of PGC1α rendered the 
cells more susceptible to lead insult and induced increased ROS generation 
and loss of mitochondrial membrane potential (FIG. 3.7), overexpression of the 
protein did not confer any protection against lead. Indeed, interestingly, I found 
that introduction of exogenous PGC1α had the opposite effect to what was 
expected – it made the cells more susceptible to lead-induced toxicity (Fig 3.9). 
Nevertheless, in PGC1α overexpressing cells, I still observed higher levels of 
Mfn1 mRNA. 
Having shown that lead induces ROS generation I sought to test whether 
this elevation of reactive oxygen species levels plays an upstream role in the 
cellular lead response. Since use of NAC, an antioxidant, did not prevent 
changes in mitochondrial function following lead exposure (3.15), it was 
concluded that ROS do not play an upstream role in the lead-induced signalling 
cascade.   
Since lead is known to mimic calcium and disrupt its cellular balance, the 
next candidate for an upstream toxicity regulator was Ca2+. I found that BAPTA 
(a calcium chelator) prevented lead-induced mitochondrial depolarisation and 
cell death (Fig. 3.17). I showed that the heavy metal causes release of calcium 
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from the ER stores and leads to elevated levels of this cation in the cytoplasm 
(Fig. 3.16). Interestingly, knockdown of BAP31, an ER-protein known to 
regulate ER calcium signalling as well as bridge the mito-ER interface, also 
helped to diminish the negative effect of lead on DA neurons (Fig. 3.19). 
Moreover, upon exposure to lead, the expression of calcineurin, which has 
been shown to control expression of PGC1α, displayed the same pattern as 
previously observed for this transcription co-activator (Fig. 3.21). I showed that 
the effects of lead on DA neurons is not a secondary consequence of microglial 
activation (Fig. 3.22). All of these findings are summarised in figure 4.1 below.  
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Figure 4.1. The possible mechanism of lead-induced disruption of neuronal calcium 
balance and its impact on mitochondrial function and morphology.  
As lead enters the cells it causes release of ER calcium (2) which is possibly mediated by 
Bap31 cleavage (1). Calcium causes activation of calcineurin which in turn contributes to 
increased expression of PGC1α and, as a consequence, its downstream targets (3). PGC1α 
triggers mitochondrial biogenesis as well as, initially, a mitochondrial adaptive response via 
regulation of mitochondrial dynamics (4). Upon prolonged exposure to lead (and extended 
period of increased PGC1α expression) altered mitochondrial function and ROS generation 
contribute to loss of mitochondrial membrane potential and cellular demise (5). 
 
 
 
4.2 Concentration-dependent effect of lead on mitochondrial 
function 
 
While lead neurotoxicity is a widely-recognized phenomenon, it is hard 
to establish what concentrations of this heavy metal should be used for in vitro 
studies that would adequately reflect real-world, clinically relevant exposure 
levels. Sensitive methods are still being developed that would allow for a 
reliable post-mortem tissue analysis to detect the levels of heavy metals, such 
as lead, in the brain (Dobrowolska, Dehnhardt et al. 2008). In vitro 
investigations described in the literature have used a wide range of 
concentrations of lead acetate (a water-soluble inorganic form of lead also used 
in the present research) ranging from 0.1 to >100 μM (Minnema, Greenland et 
al. 1986, Zurich, Eskes et al. 2002, Deng, McKinnon et al. 2001, Brinck, 
Wechsler 1989). The concentration-effect relationship for the heavy metal 
varies with the type of cells under investigation as well as their maturity, as 
noted by Deng and co-workers (2001) who showed that exposure to lead 
acetate at 100 μM for 7-days was much more deleterious to mature 
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oligodendrocytes than to oligodendroglial progenitors. Due to the uncertainty 
regarding an appropriate range of lead concentrations to use, a preliminary 
experiment was performed to establish the appropriate treatment regimen for 
future experiments (Fig. 3.1).  
 
These studies established that suitable concentrations of lead acetate to 
use in the experiments were 5, 100 and 500 µM (Fig. 3.2). It was interesting to 
note that despite a 20-fold concentration difference between 5 µM and 100 µM 
leadacetate, the effects on mitochondrial superoxide generation and membrane 
depolarisation were comparable. Since both concentrations only slightly 
increased cell death, both of these concentrations were classified as tolerated. 
In contrast, 500 µM had a much more deleterious effect on mitochondrial 
function and subsequently induced excessive cell death (Fig. 3.3); therefore 
this concentration was classified as toxic. Surprisingly, while most parameters 
of mitochondrial function remained unaffected by the tolerated concentrations 
of lead, spare respiratory capacity (SRC) was lost with all of the treatments, a 
previously unreported effect of lead (Fig. 3.4). This finding is consistent with the 
stochastic mitochondrial failure model proposed by Choi and co-workers (2009) 
to explain the importance of mitochondrial SRC in neurodegeneration. SRC 
provides an indication of the amount of extra ATP that can be produced by 
oxidative phosphorylation in case of a sudden increase in energy demand. In 
this case, it is possible that loss of SRC caused by exposure of DA neurons to 
lead could remain covert for long periods of time until the cells are subject to an 
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unusual energy demand, such as experienced by neurons in an aging brain, 
where cells suffer from impaired respiration rate linked to reduced activity of 
electron transport chain proteins, mutations in mtDNA, increased ROS 
production and decreased mitochondrial biogenesis (Yin, Boveris et al. 2014, 
Navarro, Sanchez Del Pino et al. 2002, Navarro, Boveris 2007). This 
observation could potentially help to explain why life-time exposure to lead 
causes neurodegeneration at old age. Depletion of the SRC has been 
previously linked to a range of pathologies affecting high energy-requiring cells 
such as neurons (Nicholls 2008, Yadava, Nicholls 2007).  
 As exposure to both of the concentrations of lead tolerated by N27 
cells resulted not only in cellular survival but also in a very similar mitochondrial 
response (despite the 20-fold concentration difference) I suspected the 
presence of a protective mechanism, enabling the cells to survive against lead 
insult up to a toxic threshold.  
Knowing that PGC1α is a well-recognised master regulator of 
mitochondrial metabolism (Austin, St-Pierre 2012), also previously implicated 
in PD (Shin et al. 2012), I investigated whether it played a role in the cellular 
response to lead exposure. An increased expression of PGC1α and modulation 
of its downstream targets, including genes regulating mitochondrial biogenesis 
was observed only at 100 µM lead (Fig. 3.5). In vivo experiments confirmed an 
increase of PGC1α expression in substantia nigra and striatum of animals 
exposed to lead in drinking water (Fig. 3.12). In view of the fact that 
downregulation of PGC1α increased cellular susceptibility to lead (Fig. 3.7), I 
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concluded that it acts to protect the cells by promoting mitochondrial 
biogenesis, boosting their function and suppression of ROS formation (St-
Pierre, Drori et al. 2006). PGC1α has previously been reported to play a 
protective role against a number of neurodegenerative conditions (Katsouri, 
Parr et al. 2011, O'Donnell, Lulla et al. 2014) and it is also known to respond to 
ROS by inducing a cellular ROS scavenging program (Spiegelman 2007). I 
believe that at low lead levels, slightly increased ROS production acts as a 
retrograde nuclear signal to improve mitochondrial function and adapt to the 
stressor, a phenomenon known as mitohormesis (Tapia 2006). Possibly, at low 
lead levels (5 µM) the cellular reaction to the toxicant is very subtle and there is 
no or very little adaptive response. At 100 µM, the cellular response is such that 
it triggers adaptation which is aimed at restoring cellular parameters to normal 
levels. Thus, I show for the first time that sub-lethal doses of lead induce low-
level stress which triggers an adaptive response, mediated by PGC1α. I 
confirmed the important role played by PGC1α by stably reducing the level of 
the protein which made the cells more prone to lead insult. These 
concentration-dependent effects of lead are a good illustration of a toxicity 
pathway as envisaged by the National Research Council (Krewski, Acosta Jr et 
al. 2010) 
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Figure 4.2. Concentration-dependent transition of response of cells to lead exposure. 
Exposure of cells triggers a toxicity pathway involving upregulation of PGC1α.  1) At low 
tolerated concentrations of lead (1 µM), there is minimal perturbation of the cells; 2) At high 
tolerated concentrations of lead (100 µM), upregulation of adaptive responses ensure there is 
minimal progression to toxicity; 3) At toxic concentrations of lead (500 µM), there is collapse of 
homeostasis and progression to toxicity (adapted from Krewski et al, 2010). 
 
Having detected an increase of PGC1α transcript levels at 500 µM only 
shortly after exposure to lead (3h; Fig. 3.6), and a decline to normal levels after 
exposure for 48 h (Fig. 3.5), I concluded that at toxic concentrations, although 
the adaptive response of the cell is initially triggered, it becomes overwhelmed 
beyond the homeostatic ability of the cell to counteract the insult and there is 
progression to toxicity.  I concluded that lead modulates PGC1α expression in 
a dose-and time-dependent manner.   
 
1 
2 
3 
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Interestingly, overexpression of PGC1α did not confer increased 
protection against lead, as initially expected and as seen in a number of models 
of PD (O'Donnell, Lulla et al. 2014, Mudò, Mäkelä et al. 2012). Upon treatment 
with lead, cells overexpressing PGC1α showed an increased level of apoptosis 
compared with the wild-type population (Fig. 3.9). This observation led me to 
the conclusion that the role of PGC1α might be bifunctional. While it helps the 
cell to respond to oxidative stress, prolonged expression of non-physiological 
levels of PGC1α protein seem to have a deleterious effect on mitochondrial 
function and viability of the cells. Ciron and co-workers (2012) have previously 
shown that sustained expression of PGC1α in dopaminergic neurons leads to 
neurodegeneration due to altered cellular metabolism, respiration uncoupling 
and a decrease in mitochondrial membrane potential. Cardiac-specific 
overexpression of PGC1α leads to profound changes in the ultrastructure of 
mitochondria and cardiomyopathy (Russell, Mansfield et al. 2004). Clark and 
co-workers (2012) have recently shown that overexpression of PGC1α in SN of 
mice led to a significant loss of dopaminergic cells, marked by a reduction of 
TH levels, after exposure to MPTP, while no DA neuronal cell loss was 
observed in the wild type mice, indicating a sensitisation of the cells to the toxic 
insult, rather than PGC1α-induced neuroprotection. Therefore, I postulate that 
the neurotoxic effect of lead could be mediated by increased expression of 
PGC1α which, while initially beneficial as part of an adaptive, mitohormetic 
response, could lead to lethal changes in cellular metabolism when sustained 
for a prolonged period of time, characteristic of chronic exposure.  
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4.3 The effect of lead on mitochondrial dynamics 
 
Since I observed that changes in the expression of PGC1α are 
accompanied by structural alteration of mitochondrial filaments I speculated 
whether this transcription co-activator has a direct impact on this aspect of 
mitochondrial biology. There has been very little research investigating the role 
of PGC1α in control of mitochondrial dynamics, a process very important for 
optimal mitochondrial functioning as well as apoptosis induction (Detmer, Chan 
2007). It has been previously suggested that PGC1α promotes mitochondrial 
fusion via co-activation of Mfn2 expression (Cartoni, Leger et al. 2005). 
Moreover, it has recently been proposed that PGC1α plays a role in regulation 
of MFN1 and apart from the direct role of PGC1α in control of MFN1, in their 
investigation Martin and co-workers (2014) also showed an association 
between PGC1α/β levels and expression of other fission/fusion genes. 
However, it has to be kept in mind that this study did not explore a direct 
interaction between PGC1 proteins and the genes mentioned above but rather 
involved looking at the association between the proteins (not PGC1α on its own) 
and mitochondrial dynamics genes.   
To examine the exact effect of PGC1α on mitochondrial dynamics I 
investigated the expression of a range of genes known to control mitochondrial 
dynamics in cells overexpressing this transcription co-activator as well as in 
wild-type cells exposed to lead (Fig. 3.10). Interestingly, apart from observing 
increased transcript levels of MFN2 (which is consistent with previously 
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mentioned observations made by Cartoni and co-workers), I made a novel 
observation of a PGC1α-induced decrease of DRP1 in vitro. It appears that the 
pro-fusion shift in mitochondrial dynamics observed at 100 µM lead is due to a 
change of transcription profile of a number of genes controlling this process. A 
similar effect was seen in cells overexpressing PGC1α, confirming the role of 
this transcriptional co-activator in the control of mitochondrial dynamics. 
Interestingly, in vivo data supported the notion of lead increasing the expression 
of mitofusins (MFN1 and MFN2), and so, promoting fusion, but I also observed 
an increase of DRP1 mRNA in vivo (Fig. 3.12). Since substantia nigra obtained 
from rats, used in these experiments, was a heterogenous mixture of different 
cells with dopaminergic neurons comprising between just 1-2% of the total cell 
population (Jenner, Olanow 2006), I looked at co-localisation of NeuN (highly 
specific as a marker of neurons) and DRP1 in SN to exclude the possibility that 
the global SN mRNA changes observed do not reflect the transcriptional state 
of dopaminergic neurons. This showed that the increase in DRP1 is specific to 
SN neurons (Fig. 3.14). 
Having confirmed that DRP1 levels are increased in SN neurons, I 
looked into the expression profile of this gene in vitro following a short exposure 
to 100 µM lead. DRP1 expression was increased at 3h but reduced after 48 h 
(Fig. 3.13). Hence, the short exposure could be representative of early events 
in vivo in DA neurons exposed to lead, such as within the first few weeks. Since 
it is difficult to assess the bioavailability of lead in substantia nigra of treated 
animals, a possibility exists that SN neurons in the experimental animals were 
exposed to a relatively low level of lead over the 14-week period of the study 
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and display characteristics of a short-term, early exposure, similar to the 
response observed in cells treated for 3h (McKim 2010). However, there are 
other possible explanations for the difference in findings and further study is 
needed.  
  
 
 
Figure 4.3. A schematic representation showing changes in the expression of 
mitochondrial dynamics genes following lead exposure, indicating where on the 
response curve are the timepoints modelled by our in vitro and in vivo experiments.  
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 ChIP data revealed that PGC1α binds to the promoter of DRP1 implying 
its direct role in the expression of this mitochondrial protein (Fig. 3.11). I believe 
that as an initial response to the insult in vivo and in vitro, PGC1α levels 
increase in response to lead, which promotes mitochondrial biogenesis. This in 
turn requires an increased expression of proteins regulating mitochondrial 
dynamics. A tight control of this vital process is essential to maintain the 
necessary balance between intracellular energy distribution and cell viability. 
However, a continuous exposure to the toxicant triggers a protective response 
which involves a shift of mitochondrial dynamics towards fusion, previously 
shown to help protect against neurodegeneration (Merrill, Dagda et al. 2011). I 
believe that while the binding of PGC1α to the promoter of Drp1 would normally 
result in increased expression of Drp1 to ensure maintenance of fusion-fission 
balance in the cell, the transcript levels of Drp1 remain low due to a possible 
absence/lack of activation of other members of the transcription complex driving 
expression of this gene, lack of transactivation or presence of an inhibitor, such 
as e.g. p160MYB (Fan, Rhee et al. 2004).  
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Figure 4.4. The proposed model of lead-induced changes in the expression of genes 
controlling mitochondrial dynamics as an adaptation to the toxic insult.  
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4.4 Reactive oxygen species do not play an upstream role in 
lead-toxicity signalling 
 
I suggested that at low lead levels slightly increased mitochondrial ROS 
production acts in a retrograde manner to convey a signal to the nucleus to 
initiate a response aimed at improving mitochondrial function and adaptation to 
the stressor, a phenomenon known as mitohormesis (Tapia 2006).  To 
investigate if lead-induced neuronal cell death could be attributed solely to 
ROS, I used NAC, as an antioxidant previously shown to prevent neuronal loss 
in certain toxicant-induced neurological disorders as well as suggested to have 
a potential application in PD patients (Bavarsad Shahripour, Harrigan et al. 
2014, Okouchi, Okayama et al. 2009, Martínez, Martínez et al. 1999), to 
determine if it could prevent lead-induced mitochondrial membrane potential 
loss and cell death (Fig. 3.15). Since NAC had no significant effect on DA cells, 
I then decided to look into the role of calcium, a ubiquitous intracellular second 
messenger. Calcium is of particular interest due to the ability of lead to mimic 
this ion in the cellular milieu (Garza, Vega et al. 2006, Needleman 2004, Simons 
1986, Simons 1993, Flora, Saxena et al. 2007, Clarkson 1993). In the present 
study, I showed that lead causes release of ER calcium stores and an increase 
of cytosolic calcium (Fig. 3.16), which causes disruption of calcium balance 
leading to mitochondrial dysfunction and DA neuronal cell death as concluded 
from the fact that BAPTA, a known calcium chelator which has been also 
suggested as a possible treatment in neurodegenerative conditions (Angel, Bar 
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et al. 2002, Spigelman, Tymianski et al. 1996), prevented the increase in 
mitochondrial ROS as well as depolarisation of this organelle (Fig. 3.17). 
Interestingly, it has been shown that calcineurin, the activity of which depends 
on Ca2+/calmodulin binding, can be activated by low concentrations of free lead 
while higher concentrations reduce its activity (Kern, Audesirk 2000). 
Consistent with this finding, my data showed a significant increase in 
calcineurin transcript levels at the tolerated concentration (100 µM) and a clear 
decrease at the toxic concentration (500 µM; Fig. 3.21). This observation 
provides a possible explanation for a differential, lead-induced dose-dependent 
expression of PGC1α. Calcineurin has previously been reported to be involved 
in regulation of expression of this transcription co-activator. Roberts and co-
workers showed that suppression of calcineurin leads to an attenuation of 
expression of PGC1α (2010). While the involvement of calcineurin in regulation 
of PGC1α remains a subject of discussion (Koulmann, Banzet et al. 2007, Lin, 
Handschin et al. 2005), these data clearly support such involvement.   
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4.5 Calcium is a key, upstream player in lead neuroxtoxicity 
 
Disruption of ER calcium stores has previously been implicated in 
neurodegeneration (Hernández‐Fonseca, Massieu 2005) and has been 
suggested as one of the mechanisms via which lead causes cognitive 
dysfunction in neonatal rats (Fan, Zhou et al. 2013). As discussed above, pre-
treatment of dopaminergic cells with BAPTA-AM (Fig. 3.17), a calcium chelator, 
prevented lead-induced mitochondrial membrane potential loss and 
subsequent cell death reflecting the upstream role played by this ion in lead 
toxicity. BAP31 is an ER-localized protein, cleavage of which produces pro-
apoptotic Bap20, which mediates mitochondria-ER cross talk through a Ca2+-
dependent mechanism (Chandra, Choy et al. 2004) Caspase-8 cleavage of 
BAP31 at the ER stimulates Ca2+-dependent mitochondrial fission, enhancing 
cell death (Breckenridge, Stojanovic et al. 2003). My data showed that stable 
knockdown of BAP31 significantly decreases activation of caspase 8 as well as 
caspase 3/7 implicating it in the cellular response to lead (Fig. 3.19).  
Interestingly, Breckenridge and co-workers (2003) have previously 
shown that overexpression of Bap20 causes ER Ca2+ release and concomitant 
uptake of Ca2+ into mitochondria with subsequent recruitment of Drp1, resulting 
in dramatic mitochondrial fragmentation. My data show that BAP31 protein is 
increased in a concentration dependent manner by lead exposure and its 
knockdown reduces lead-induced initiation of the mitochondrial cell death 
pathway. This reveals the important role played by this ER protein in disruption 
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of calcium homeostasis in response to lead insult. Together, these data and 
those of Breckenridge strongly support the involvement of ER calcium and 
DRP1-controlled fission in the response to lead exposure. However, while I 
identified calcium as the key player and I elucidated part of the mechanism of 
lead-induced neurotoxicity, it remains to be determined whether it is ER-stress 
that is triggered by lead, causing release of calcium into the cytoplasm, as 
suggested by Qian and Tiffany-Castiglioni (2003), which then has an effect on 
mitochondria and their biology, or whether lead mimics calcium itself and 
causes its imbalance via an ER-stress-independent mechanism.  
 Apart from the suggested mechanism involving calcium-ER-
mitochondria, there is another route, not explored in the present investigation, 
via which lead could exert its neurotoxic effect. While lead is known to interfere 
with haeme biosynthesis (Chisolm, Barrett et al. 1975, Roels, Bucket et al. 
1976), PGC1α has been recently shown to induce heam oxygenase-1 (HO-1) 
expression (Ali, Ali et al. 2010). Interestingly, HO-1 hyperactivity in neurons was 
shown to contribute to neurodegeneration in disorders such as PD and AD 
(Schipper, Song et al. 2009). Thus, this opens another possibility for a different 
mechanism mediating lead neurotoxicity which could be further explored in the 
future.  
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4.6 Future work 
 
 In the present study I have established a plausible mechanism of 
lead-induced neurodegeneration. While I identified a number of key events that 
occur in N27 cells and confirmed in part in vivo, in response to the insult, there 
are a number of interactions that still need to be confirmed or explored further 
to obtain a complete picture of the interaction network.    
Since I established an important, upstream role of calcium in my cellular 
model, it would be interesting to establish the precise nature of the link between 
this cation and mitochondria. Investigation of the expression of PGC1α in cells 
pre-treated with BAPTA would reveal whether it is the calcium-induced 
disruption of mitochondria and action of ROS as cellular messengers that cause 
elevation of the level of this transcription co-activator. Moreover, if BAPTA can 
prevent PGC1α induction, use of NAC could help to establish whether it is a 
direct influence of lead on calcineurin or rather ROS that drive its induction upon 
lead-exposure. Use of calcium channel blocking drugs, such as verapamil and 
diltiazem, could reveal the extent to which lead acts via ion mimicry and binding 
to Ca2+-dependent proteins rather than by disruption of Ca2+ balance by 
opening the channels.  
 Having fully assessed the role of calcium, investigation of ER 
stress, previously shown to be triggered by lead in the nervous system (Qian, 
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Tiffany-Castiglioni 2003), would allow for determination of whether binding of 
lead to GRP78 could be the very first step triggering the entire response-
cascade described in my thesis. ER stress following lead exposure could be 
assessed by looking at IRE1α phosphorylation levels, measuring levels of 
spliced/unspliced XBP-1 (IRE1α target) by RT-QPCR, or transfection of cells 
with a GFP–ATF6α fusion protein which is known to be cleaved and 
translocated in response to ER stress. Since BAP31 was previously shown to 
be cleaved during ER stress (Namba, Tian et al. 2013) and I have shown that 
its down-regulation protects the cell against lead insult, it is possible that lead 
acts via induction of ER stress response which subsequently causes ER 
calcium release. 
 To obtain a better understanding of what the exact nature of 
calcium-mitochondria interaction is after exposure to lead, a mitochondrial 
calcium dye, like Rhod-2 AM, could be used to look at the uptake of Ca2+ by the 
organelle from the cytoplasm after it is released from the ER. Moreover, 
Seahorse XF cell mito stress test kit could be used to establish whether pre-
treatment of N27 cells with BAPTA prevents loss of SRC and the decrease in 
ATP production observed in those cells.  
 In order to confirm whether my in vitro data are a good model of 
long-term exposure of dopaminergic cells to low levels of lead, an in vivo 
experiment should be performed with animals exposed to lead for a longer 
period of time (e.g. 10 months). It would be interesting to see if in those rats the 
pattern of expression of genes regulating mitochondrial dynamics changes in a 
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way promoting fusion and whether prolonged exposure would eventually cause 
degeneration of dopaminergic neurons. Moreover, injection of lentiviral PGC1α 
expressing constructs into substantia nigra of rats, followed by exposure to 
lead, could also shed more light on in vivo implications of overexpression of this 
protein since it has previously been shown to reduce the damage caused by 
PARIS overexpression in the dopaminergic neurons of substantia nigra of mice 
(Shin, Ko et al. 2011).  
 Finally, use of the available toxicogenomic databases followed by 
bioinformatic analysis to investigate the expression profiles of PGC1α, its 
targets as well as genes regulating mitochondrial dynamics and the global 
transcriptional profile in neuronal cells treated with lead, would be useful in an 
unbiased assessment of the true contribution of the cellular network identified 
in the present investigation as the one mediating lead-induced neurotoxicity.  
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